P2X RECEPTORS (PURINOCEPTOR FAMILY)

Abstract: The P2X receptor of ATP has been cloned and expressed by recombinant DNA technology, so the receptor can be prepared free from other ATP receptors. The P2X receptor enables antibodies to be prepared and is useful in screening compounds for use in a variety of diseases and conditions, including epilepsy, cognition, emesis, pain (especially migraine), asthma, peripheral vascular disease, hypertension, diseases of the immune system, irritable bowel syndrome and premature ejaculation.

Description: P2x RECEPTORS (PURINOCEPTOR FAMILY) This invention relates to the P 2X -purinoceptor, its preparation and uses. The P 2X -purinoceptor is a ligand-gated ion channel; that is, the receptor itself forms an ion channel which opens when extracellular adenosine 5' -triphosphate (ATP) binds to the receptor. There are five other classes of neurotransmitter receptors (nicotinic acetylcholine, glutamate, glycine, GABA A and 5-HT 3 ) ; these form a structurally related superfamily of ligand-gated ion channels (Barnard, Trends Biochem. Sci . 17, 368-374, (1992) ) . The P 2X -receptor now identifies a new family of this type of receptor. The unique structure of this receptor, the widespread distribution of this receptor throughout the body, and the numerous physiological roles this receptor may play, make it an important protein that can be used to identify new, therapeutically effective, compounds for the treatment of a number of pathological states. In 1929 the eminent physiologist Szent-Gyorgyi described powerful cardiovascular actions of extracellular purine nucleosides (e.g. adenosine) and nucleotides (e.g. ATP) (Drury S, Szent-Gyorgyi, J. Physiol . 68 213-237 (1929)), but it was not until 1972 that pharmacological evidence was provided to suggest the existence of distinct receptors for extracellular ATP (ie. that recognise ATP but not adenosine) (Burnstock, Pharmacological Reviews 21 509-581 (1972)) . The seminal and subsequent work on this area by Burnstock and colleagues was largely unaccepted throughout the 1970s and early 1980s until the development of a range of relatively selective ligands and techniques for directly measuring ATP release overwhelmingly substantiated Burnstock' s hypothesis (Barnard et al . , Trends Pharmacol . Sci . 15 67-70 (1994)) . In the past four or five years, unequivocal evidence for the role of ATP as a neurotransmitter has been provided for sympathetic control of blood flow to the intestine and smooth muscle tone (contractility) in genitourinary tissue such as vas deferens, bladder and ureter (Barna'rd eϋ al . [loc. ci t. ) and Evans & Surprenant, Brit. J " . Pharmacol . 106 242-249 (1992)) . Substantial indirect evidence also exists for the role of ATP as a neurotransmitter in a number of distinct neurones in the spinal cord, autonomic ganglia and certain nuclei in the central nervous system (Bean, Trends Pharmacol . Sci . 15 67-70 (1992), Evans et al . , Nature 357, 503-505 (1992) and Edwards et al . , Nature 359 144-147 (1992)) . Purinoceptors are classified as P x (adenosine as ligand) and P 2 (ATP as ligand) . The P 2 receptors are subclassified into two broad types - those that are 7-transmembrane receptors that couple to G-proteins (P 2Y , P 2U ' P 2T * and perhaps P 2Z ) and those that form a directly gated ion channel (P χ ) • Pharmacological and/or physiological evidence for subtypes of each of these types of receptors exists. The most recent nomenclature for these receptors is shown below. Various P 2 receptors have previously been cloned. P 2Y1 was cloned by the Barnard/Burnstock group (Webb et al . , FEBS Lett . 324 219-225 (1993)) based on homology with other 7-TM G-protein coupled receptors. This group used PCR technology and primers based on conserved domains of the second and sixth transmembrane regions to screen a mammalian brain cDNA library and, with final success, an embryonic chick whole-brain cDNA library. P 2Y2 /P 2U was cloned by the Julius laboratory (Lustig et al . , Proc . Na t'2. Acad . Sci . USA 90 5113-5117 (1993)) by expression cloning in the oocyte from cDΝA obtained from a ΝG108-15 neuroblastoma cell line. P 2Y3 /P 2T was also obtained by the Barnard/Burnstock group using ' the same probes and embryonic brain cDNA library used to obtain the P 2Y1 receptor (Barnard et al . , Trends Pharmacol . Sci . 15 67-70 (1994)). However, as yet, cloning of the P 2X receptor has remained an elusive goal. The prior cloning exercises undertaken for the other P 2 receptors do not provide an adequate lead to enable the P 2X receptor to be cloned. First, all the above purinoceptors are G-protein coupled 7-TM proteins. Their myriad functions (like those of all 7-TM receptors) occur through G-protein activation of one or more second messenger systems. There are over 200 currently identified proteins which belong to this 7-TM/G-protein coupled family. Agonists at these receptors activate cascades of intracellular transduction pathways, often involving several enzymes; the response of the cell is inherently slow (several seconds to minutes) and changes in excitability are subtle if they occur. In contrast, the P 2X receptor is a fundamentally different type of purinoceptor that incorporates an ion channel. Activation of P 2X receptors is rapid (milliseconds) , has predominately local effects, and brings about immediate depolarisation and excitation. Secondly, the tissue distribution of the P 2X receptor is distinctly different from other purinoceptors, and the physiological roles differ from other purinoceptors. One of the principal established ways to clone a receptor is based on sequence relatedness of the nucleotides that encode the amino acids of the receptor protein; it depends on there being a fairly high level of homology between a known sequence and that of the unknown receptor. This method was used to clone the P 2Y1 form (above) . Several laboratories, including that of the applicants, invested significant effort in obtaining the P 2X receptor using PCR techniques and primers based on conserved regions of various ligand-gated ion channels (ie. nicotinic ACh, GABA, glutamate, 5-HT 3 ) . This approach failed. With hindsight, this failure can be rationalised, as it can now, but only now, be seen that the structure of the P 2X receptor bears no homology with any of these ligand-gated ion channels. For the same reason, approaches based on fragment hybridisation would not succeed. However, by adopting a different approach, it has now been found possible to clone the P 2X receptor, and it is on this achievement that the present invention is in part based. According to a principal aspect of the present invention, there is provided a recombinant or isolated DNA molecule encoding a P 2X receptor, wherein the receptor: (a) has the amino sequence shown in Figure 1, Figure 2, Figure 3 or Figure 4,* or (b) is substantially homologous to the sequence shown in Figure 1 , Figure 2, Figure 3 or Figure 4; or a fragment of such a DNA molecule, which fragment includes at least 15 nucleotides taken from nucleotides 1 to 813 shown in Figure 1, the full nucleotide sequences shown in Figures 2 and 3, or from nucleotides 1 to 1744 shown in Figure 4. The sequence shown in Figure 1 is a cDNA sequence that encodes a rat vas deferens P^ receptor. This sequence is 1837 bases in length and encodes a protein of 399 amino acids. As was determined after the receptor was cloned, approximately one half of the protein-encoding sequence, from nucleotides 814 onwards, had been discovered previously but the function of the previously cloned sequence was not known except that it appeared to be implicated in apoptotic cell death (Owens et al., Mol. Cell. Biol. 11 4177-4188 (1991)); the Owens et al. sequence lacks a translation initiation site and could not be made into protein. (In Figure 1, the upstream portion of the reported sequence of Owens et al., namely PQLAHGCYPCPPHR, which is not shared with the P^ receptor, is shown for comparative purposes and does not form part of the invention.) Preferably the Figure 1 sequence fragments are taken from nucleotides 1-810. Often the Figure 4 sequence fragments are taken from nucleotides 1-777. The sequence shown in Figure 2 is a cDNA sequence that encodes a rat superior cervical ganglion P^ receptor. The sequence shown in Figure 3 is a cDNA sequence that encodes a rat dorsal root ganglion P^ receptor. The sequence shown in Figure 4 is the cDNA sequence that encodes a human P_ χ receptor. The cDNA was isolated from the human urinary bladder using a rat P 2X probe. It is 2643 bases long and encodes a 399 amino acid protein having an amino acid sequence which is highly homologous with the amino acid sequence of the rat P^ receptor isolated from rat vas deferens and with the rat P_yr receptors isolated from a rat superior cervical ganglion and from a rat dorsal root ganglion. Recently we have become aware of an expressed sequence tag corresponding to residues 1745-1933 (Proc. Natl. Acad.Sci. USA 91,10645-10649 (Oct. 1994). Sequences which are substantially homologous to the Figure 1, Figure 2, Figure 3 or Figure 4 amino acid sequence include those which encode proteins having at least 40%, 50%, 60%, 70%, 80%, 90%, 95% or 99% homology in increasing order of preference. A protein having at least 99% homology with the amino acid sequence of Figure 1 , Figure 2, Figure 3 or Figure 4 will have no more than four amino acid variations from such a sequence. Preferred substantially homologous sequences include P^ sequences from other species. Thus for the rat P 2X receptor sequences a preferred substantially homologous sequence is a human P 2 x sequence. One method of determining sequence homology is disclosed in WR Pearson and DJ Lipman, Proc NatlAcad Sci USA 85:2444-2448 (1988). Fragments may of course be larger than 15 nucleotides. Fragments encoding substantially the whole of the P_χ rat receptors or human receptor may be expected to share the biological activity of the receptor, or at least some of its biological activities. Shorter fragments may be useful for encoding one or more selected domains of the receptor, or simply as probes for detecting or identifying other useful DNA sequences, including those encoding substantially homologous proteins. Fragments of at least 20, 30 or 50 nucleotides may be more frequently of use than shorter ones. DNA molecules of the invention are useful for a number of purposes. First, and not least, the P 2X cDNA shown in Figure 1, in Figure 2, in Figure 3 and in Figure 4 enables the relevant proteins to be expressed in living cells. This would not be possible with fragments of the cDNA. However not only are fragments of DNA within the scope of the invention, for the various purposes mentioned above, but also genomic and other sequences of DNA (including synthetic DNA and "minigenes", which include at least one, but not all, of the introns naturally present in the gene) are included within its scope. cDNA sequences encoding the rat receptor proteins or human P 2X receptor protein may be preferred in some circumstances because such sequences are smaller than either genomic or minigene DNA and therefore more amenable to cloning manipulations. The P 2X receptor protein can be stably expressible in Chinese hamster ovary (CHO) cells, as will be described below. Still on the subject of expression, while it would be possible to express genomic DNA in eukaryotic cells, it is much more difficult to manipulate the DNA for insertion into host cells due to the larger size that commonly results from introns. The size is particularly important for the expression of RNA; very long cRNAs -- the size of whole genes -- are difficult to make in sufficient quantity. On the other hand, expression from RNA is much preferred at least for the investigation of ion channel proteins, because the Xenopus oocyte is sufficiently large to be studied easily by electro- physiological methods. Secondly, the cDNA sequences encode proteins that, in their predicted folding within the membrane, differ from other known proteins. This is advantageous because, based on historical precedent, this will lead to the discovery of a large family of related proteins and these may have functional roles unrelated to signalling mediated by ATP. Thirdly, knowledge of the protein sequences encoded by rat and human P 2X cDNA allows the development of molecular models that predict the detailed disposition within the membrane. It further allows the correctness of such models to be determined by expression of mutagenised proteins. These two approaches are advantageous because they may permit the molecular design of complementary therapeutic agents that activate or block the receptor. Fourthly, the P 2X cDNA sequences allow the distribution of the RNA that encodes this receptor, as well as the receptor protein itself, to be mapped in human tissues. RNA distribution can be determined by in situ hybridisation. Such hybridisation studies are disclosed in the present examples. Knowledge of a deduced amino acid sequence from cDNA allows synthetic peptides to be made that can be used to generate antibodies that selectively recognise a P 2X receptor. Thus a P 2X protein can be mapped by immunohistochemistry. This may suggest novel therapeutic applications for drugs that activate or block the P 2X receptor, that can not be predicted on the basis of less sensitive current methods for localising the receptor (radioactive ligand binding) . Fifthly, rat P 2X cDNA is advantageous because it can allow the isolation of a closely related cDNA from human tissue. Sixthly, the isolation of the human P 2X cDNA clone will enable a human genomic clone to be obtained. It is probable that mutations of this gene will be discovered that lead to human genetic disease. The analysis of such mutations may lead to appropriate treatments of diseases or disorders caused by such mutations. In one aspect of the present invention rat vas deferens P 2X receptor was cloned by a method which does not require prior inference about structure. Tissues were chosen that were believed to be rich in the RNA for the receptor of interest. A number of tissue sources were tried but they did not provide RNA that led to ATP responses in oocytes. Eventually, vas deferens was chosen. From extracted polyadenylated RNA, a cDNA library or bank that corresponds as far as possible to the DNAs in the tissue was constructed. It was not assured, either before work began or until it was satisfactorily completed, that a satisfactory cDNA library in which the rat P 2X gene was represented could be constructed; nevertheless, this was achieved in plasmid pBKCMV. An individual clone within the library that contains the rat vas deferens P 2X cDNA of interest was detected by progressive fractionation of the library; at each step the fraction was tested to determine whether RNA made from it can direct the formation of the protein of interest. More specifically, RNA was transcribed in vitro from the cDNAs in the library (approximately 2 million) and the RNA ("cRNA") mixture was injected into immature Xenopus oocytes. cRNA is very susceptible to inadvertent enzymatic degradation, so all procedures were carried out under sterile conditions. The cDNA pools were made by the miniprep procedure and therefore contained large amounts of E. coli RNA; this difficulty was overcome by precipitating any RNA before the cRNA was transcribed. Detection of the protein can in principle be done by radioactive ligand binding or by a functional response. The activation of G proteins in the Xenopus oocyte and the subsequent cellular response was used to obtain the P 2Y /P 2U receptor. In the present work, a decision was made to use the opening of the integral ion channel of the P 2X as the response. Individual oocytes were screened two days after injection to determine whether they had made P 2X receptor protein in their membrane. This was done by recording the current flowing across the oocyte membrane when ATP (30 μM) was applied to the outside of the oocyte; if the P 2χ receptor has been produced, a small transient current would be expected. However, testing for expression of the receptor was not straightforward, as some batches of oocytes exhibit responses to ATP because they naturally express other kinds of ATP receptor. This difficulty was overcome as follows: when an oocyte responded to ATP with the expected current this was further tested by blockade with a P 2X receptor antagonist (suramin) . The cDNA fraction that gave led to the positive response in such an oocyte was further divided, and each fraction was again tested. Such progressive fractionation led to isolation of a single clone. The insert in the plasmid was sequenced; the sequence is shown in Figure 1. This sequence was used to design PCR primers which were used in the cloning of cDNA encoding a P 2X receptor from a rat superior cervical ganglion (see Figure 2) . A similar procedure was then used .in the cloning of cDNA encoding a P 2X receptor from a rat dorsal root ganglion (see Figure 3) . DNA in accordance with the invention will usually be in recombinant or isolated form and may be in the form of a vector, such as a plasmid, phagemid, cosmid or virus, and in some embodiments contains elements to direct expression of the protein, for example in a heterologous host. Non-expressible vectors are useful as cloning vectors. Although DNA in accordance with the invention may be prepared synthetically, it is preferred that it be prepared by recombinant DNA technology. Ultimately, both techniques depend on the linkage of successive nucleotides and/or the ligation of oligo- and/or poly- nucleotides. The invention enables, for the first time, P 2X receptor to be prepared by recombinant DNA technology and hence free from protein with which it is naturally associated or contaminated (such as the P 2U or, particularly, P 2Y receptor, or other ATP receptors or binding proteins) , and this in itself forms another aspect of the invention. The protein will generally be associated with a lipid bilayer, such as a cell, organelle or artificial membran . P 2X receptor prepared by expression of DNA in accordance with the first aspect may be glycosylated, but does not have to be. Generally speaking, receptor proteins and ion channels that are glycosylated will also function after carbohydrate removal or when expressed in cells that do not glycosylate the protein. However, there are often important quantitative differences in the function between the glycosylated and non-glycosylated protein. In the case of the rat vas deferens P 2X receptor, we believe that the native protein is glycosylated because it has a molecular weight of 62 kd when purified from the rat vas deferens, as compared to the molecular weight of 45 kd for the cloned protein. Similar results were obtained for the human P 2X receptor (see later) . There are also several asparagine residues in the extracellular domain that are likely sites of sugar attachment. Knowledge of the amino acid sequence of a P 2X receptor enables the protein or peptide fragments of it to be prepared by chemical synthesis, if required. However, preparation by expression from DNA, or at least translation from RNA, will usually be preferred. Particularly useful peptide fragments within the scope of the invention include epitopes (which may contain at least 5, 6, 7, 10, 15 or 20 amino acid residues) of the P 2X receptor which are immunologically non-cross reactive with the RP-2 polypeptide disclosed in Owens et al . , loc. cit. A P 2X receptor, and fragments of it, can be used to prepare specific polyclonal and monoclonal antibodies, which themselves form part of the invention. Polyclonal and monoclonal antibodies may be prepared by methods well established in the art. Hybridoma and other cells expressing monoclonal antibodies are also within the invention. RNA encoding a P 2X receptor, transcribable from DNA in accordance with the invention and substantially free form other RNAs, also forms part of the invention, and may be useful for a number of purposes including hybridisation studies, in vi tro translation and translation in appropriate in vivo systems such as Xenopus oocytes. The invention also relates to host cells transformed or transfected with a vector as described above. Host cells may be prokaryotic or eukaryotic and include mammalian cells (such as COS, CHO cells and human embryonic kidney cells (HEK 293 cells)), insect cells, yeasts (such as Saccharomyces cerevisiae) and bacteria (such as Escherichia coli ) . Host cells may only give transient expression of the receptor, as in the case of COS cells, but for preference the host cells are stably transfected with the vector. Host cells which appropriately glycosylate the receptor are preferred. A CHO cell line or any other cell line that stably expresses a P 2X receptor can be used for electrophysiological, calcium-influx, calcium-imaging and ligand-binding studies. Host cells which do not express the receptor may still be useful as cloning hosts. A P 2X receptor prepared by recombinant DNA technology in accordance with the invention has a number of uses, either in si tu in a membrane of the expression host or in in vi tro systems. In particular, the receptor can be used as a screen for compounds useful in a variety of human (or other animal) diseases and conditions, as will now be briefly described. Such compounds include those present in combinatorial libraries, and extracts containing unknown compounds (e.g. plant extracts) . Epilepsy Epilepsy results from overexcitation of distinct neurones in specific regions of the brain, in particular in the hippocampus. Functional ATP P 2X receptors are known to be present in some hippocampal neurones. If the P 2X receptors are expressed on inhibitory interneurons, then receptor agonists would be therapeutically useful. If the receptor is expressed on principal (pyramidal or granule) cells, then receptor antagonists will be useful. If will now be possible to determine which classes of neuron express the receptor. Cognition Hippocampal neurones respond to ATP by activation of a P 2X receptor; these areas are of primary importance to cognition. It is now possible to determine the cellular localisation of the P 2X receptor with in the hippocampus; depending on this localisation, either agonists or antagonists might be effective to enhance memory. Emesis The acute trigger for emesis is rapid contraction of smooth muscle of the upper gastrointestinal tract. Activation of ATP P 2X receptors present on smooth muscle of the GI tract, in particular the stomach and trachea, results in strong, rapid muscle contractions. P 2X - antagonists selective for visceral smooth muscle could be useful for emesis. Furthermore, P 2X receptors are known to be expressed in the nucleus of the tractus solitarius (Ueno et al., J. Neurophysiol . 68 778-785 (1992)) and may be involved in transmission from primary visceral afferents; this could be blocked by selective P 2X antagonists. Pain First, P 2X receptors are expressed in dorsal horn neurones of the spinal cord. Activation of these neurones by ATP causes fast depolarizing, excitatory responses (Jahr & Jessell, Nature 304 730-733 (1983)) ; if a component of the transmission from nociceptive fibres is mediated by ATP then this could be blocked by a P 2X antagonist . Secondly, ATP is one of the most noxious substance known when applied intradermally. This is because it activates directly the peripheral terminals of small diameter nociceptive fibres; it is known that the cell bodies in the dorsal root ganglion express P 2X receptors. A P 2X antagonist would be a peripherally active analgesic, and is likely to be effective in migraine. Asthma Bronchial smooth muscles contract in response to activation of P 2X receptors. This may occur in response to ATP released from sympathetic nerves, or from local immune cells. P 2X antagonists may help to prevent stimulus-evoked spasms of bronchial smooth muscle and thereby reduce the frequency and/or severity of asthmatic attacks. Peripheral vascular disease It is becoming clear that ATP and not noradrenaline is the primary vasoconstrictor neurotransmitter in small resistance arteries - those that comprise over 70% of total peripheral resistance. This has been shown for many vessels (Westfall et al . , Ann . N. Y. Acad. Sci . 603 300-310 (1991)) . A selective antagonist could be used for local collateral vaso- dilation. Hypertension Hypertension that is associated with increased sympathetic tone could be treated with P 2X receptor antagonists, because ATP is a major excitatory transmitter to many resistance vessels in several species including man (Westfall et al . , loc . ci t . and Martin et al . , Br. J. Pharmacol . 102 645-650 (1991)) . Diseases of the immune system A molecule identical to part of the P 2X receptor has been cloned from thymocytes that have been induced to die (Owens et al . , loc . ci t . ) . The selective expression in these conditions implies that a molecule closely related to the P 2X receptor plays a role in the apoptosis that is an integral part of the selection of immunocompetent cells. The molecule described by Owens et al . (RP-2) was incomplete and could not have been translated into protein. The cloning of the P 2X receptor will now allow the isolation of full length RP-2 clones, their heterologous expression and the determination of their functional roles. Irritable bowel syndrome ATP is an important transmitter to the smooth muscles of the intestinal tract, particularly in the colon. It is also a transmitter between neurons in the enteric nervous system, by activating P 2X receptors (Galligan, Gastroenterology , in press) . Antagonists at P 2X receptors may therefore have utility in the management of this condition. Premature ejaculation This could be prevented by preventing stimulus-evoked contraction of vas deferens smooth muscle. P 2χ receptors are highly expressed in this tissue; antagonists at this site would prevent vas deferens contractility during sympathetic excitation. Cystitis P 2X receptors may be implicated in increased bladder sensitivity in patients with cystitis. Thus antagonists of such P 2X receptors may be useful in treating cystitis. Useful agonists and antagonists identified as described above also form an aspect of the invention. The cloning of the hP 2X receptor is an important aspect of the present invention. hP 2X is the first human member of a multigene family of ionotropic purinoceptors. Its strong similarity with P 2X , isolated from rat vas deferens and with P 2X isolated from rat superior cervical ganglion or from rat dorsal root ganglion, suggests that it is a human homolog of the rat proteins. The present inventors have found that differences between these two sequences are nearly all conservative substitutions of hydrσphilic residues. Surprisingly, hP 2X has only 41% identity with the other reported P 2X receptor, that from rat PC12 cells (Brake et al , New structural motif for ligand-gated ion channels defined by an ionotropic ATP receptor Nature 371: 519-523 (1994)). The PC12 derived receptor was proposed to have a similar membrane topography and shares the conserved spacing of cysteine residues, indicated for the two smooth muscle sequences in Figure 5. The computed molecular weight of the hP 2χ polypeptide (45 kd) agrees with that of the in vi tro translation product when made in absence of pancreatic microsomal membranes. A larger product, 60 kd, produced in presence of microsomes suggests glycosylation and supports the idea of a central extracellular domain. The predicted hP 2X protein thus has the general features of other cloned members of this family (Valera et al , A new class of ligand-gated ion channel defined by P 2χ receptor for extracellular ATP Nature 371: 516-519 (1994); Brake - supra) : a large, cysteine-rich extracellular central domain flanked by two transmembrane spans and short internal Ν- and C-termini. The distribution of the hP 2X mRΝA was examined by northern blot analysis. Hybridisation of a principal 2.6 kb species was seen in all RΝA samples tested, with the exception of brain. A smaller, 1.8 kb band, observed in spleen, and lung mRNAs could be due to a shorter 3' untranslated portion of the mRNA, as occurs for P 2X mRNA from the rat vas deferens. The hybridisation observed in thymus, lung, spleen and liver RNA may reflect the content of smooth muscle in those organs. However, hP 2X is likely to have roles in other cell types, as demonstrated by its presence in adrenal gland, and the hemopoetic cell line HL60. The strong induction of hP 2x mRNA by HL60 differentiation may reflect a parallel observation in rat in which the smooth muscle form of P 2X mRNA can be induced in immature thymocytes by dexamethasone (RP2 mRNA; Owens et al , Identification of mRNAs associated with programmed cell death in immature thymocytes J J Molec Cell Biol 11: 4177-4188 (1991)). The present invention has enabled the first comprehensive pharmacological characterization of a cloned P 2X - purinoceptor to be made. The time course of the responses to ATP and the sensitivity to , β, -methylene ATP are similar to those reported for the native hP 2x in urinary bladder (Inoue & Brading, Human, pig and guinea- pig bladder smooth muscle cells generate similar inward currents in response to purinoceptor activation Br J Pharmacol 103: 1840-1841 (1991)) . Thus the functional properties of some native P 2X purinoceptors can be obtained by the expression of a single molecular species. The agonist induced current recorded from ooctyes expressing the hP 2X clone gives a direct measure of the activation of P 2X -purinoceptors in a system with low levels of endogenous ectonucleotidase activity. The agonist profile 2MeSATP^ATP>o;, β , -meATP for hP 2X is similar to that of the cloned rat vas deferens P 2X -purinoceptor. The high potency of ot , β , -meATP in whole tissue studies ( , β , -meATP >> 2MeSATP . >ATP) probably reflects, its resistance to ectonucleotidases. The concentration-effect curves for ATP, 2MeSATP and 2- chloro-ATP were superimposable, indicating that these particular substitutions at the 2' position on the adenine ring do not affect agonist binding to the P 2X - purinoceptor. The agonist activity of AP 5 A is likely to be because diadenosine phosphates (AP 5 A, and AP 6 A) released from the platelets can act as vasoactive agents through activation of P 2X -purinoceptors. Preferred features of each aspect of the invention are as for each other aspect, mutatis mutandis . The invention will now be illustrated by the following examples. The examples refer to the accompanying drawings, in which: FIGURE 1 shows DNA and amino acid sequences of the rat vas deferens P 2X receptor as determined in Example 2. (SEQ ID NO 4) . FIGURE 2 shows DNA and amino acid sequences of a rat superior cervical ganglion P 2X receptor, as determined in Example 11. (SEQ ID NO 5) . FIGURE 3 shows DNA and amino acid sequences of a rat dorsal root ganglion P 2X receptor, as determined in Example 12. (SEQ ID NO 6) . FIGURE 4 shows DNA and amino acid sequences of a human P 2X receptor as determined in Example 6. (SEQ ID NO 7) 5 FIGURE 5 shows the alignment of the predicted amino acid sequence of hP 2X with the rat vas deferens P 2X , and in vi tro translation of hP 2x protein. TM1 and TM2 filled boxes indicate the hydrophobic 10 regions and boxed amino acids indicate the differences between the two sequences, o indicates conserved cysteine residues. * Indicates potential sites of N-glycosylation. • 15 FIGURE 6 shows an SDS-PAGE analysis of 35 S-methionine labelled hP 2X protein. Lanes 1 and 2 show in vi tro coupled transcription/translation of pBKCMV-hP 2X cDNA 20 in the absence and presence of microsomal membranes, respectively. FIGURES 7 AND 8 show Northern analyses of the hP 2x 25 cDNA, wherein: A) FIGURE 7 shows Northern blot with 8 μg of total RNA from differentiated HL60 cells. 30 0 indicates HL60 cells without treatment; PMA2 and PMA3 indicate respectively cells treated 2 days, and 3 days with PMA; DMSO indicates cells treated 6 days with DMSO; dcAMP indicates cells treated 5 days with dibutryl cAMP; UB indicates 100 ng of polyA + RNA from human urinary bladder; and B) FIGURE 8 shows distribution of hP 2X in human tissues . Lanes contained 1 μg polyA + RNA except for the urinary bladder which contained 0.2 μg of polyA + RNA. FIGURES 9, 10 and 11 show the response of oocytes expressing hP 2X to purinoceptor agonists, wherein: A) FIGURE 9 shows traces which show inward currents evoked by ATP, 2 me SATP and , β , me ATP (0.1, 1, and 100 μM) . Records for each agonist are from separate oocytes,* B) FIGURE 10 shows concentration response relationships of full P 2X -purinoceptor agonists. Data are expressed relative to the peak response to 100 μM ATP; and C) FIGURE 11 shows concentration response of partial P 2x -purinoceptor agonists. Data are fitted with a Hill slope of 1 (n = 4-8) . FIGURES 12 and 13 show the effects of P2- purinoceptor antagonists of hP 2X mediated responses, wherein,* A) FIGURE 12 shows concentration response curves for ATP in the presence of the P2-purinoceptor agonist suramin (1, 10 and 100 μM) (n = 4 for each point) ; and B) FIGURE 13 shows concentration dependence of suramin, DIDS, PPADS and P5P in inhibiting the response to 10 μM ATP (n = 4 for each point) . FIGURE 14 shows the results of the functional characterisation of rat superior ganglion P 2X receptors (as encoded by clone 3, described in Example 10) . These experiments provided electrical recordings from transfected HEK293 cells. Top left : Superimposed currents evoked by ATP (30 μM) during the time are indicated by the bar. Holding potential was changed from -70 to 20 mV. Top right : Peak current as a function of membrane potential. Bottom left : Superimposed currents evoked by ATP, from 1 to 300 μM. Bottom right : Concentration-response curves for ATP and α/3methylene-ATP (points are mean ± s.e. mean for 5 - 8 experiments) . FIGURE 15 shows the inhibition of currents caused by various substances acting on the clone 3 form of the P 2X receptor (as described in Example 11) , compared with PC12 and human bladder forms in HEK293 cells. Top : inhibition by suramin. Middle : inhibition by PPADS. Bottom; inhibition by pyridoxal 5-phosphate. EXAMPLES (i) RAT VAS DEFERENS P 2χ RECEPTOR EXAMPLE 1 Cloning of the Rat vas deferens P 2χ Receptor Total RNA was isolated by the guanidinium isothiocyanate method (Sambrook et al . , "Molecular Cloning: A Laboratory Manual" Cold Spring Harbor Laboratory Press, second edition (1989) ) from vas deferens of 4 weeks old Sprague-Dawley male rats, and the poly A+ RNA was subsequently purified by oligo(dT) -cellulose. First strand cDNA primed with the sequence 5'- GAGAGAGAGAGCGGCCGCTTTTTTTTTTTTTTT-3' (SEQ ID NO 1) was synthesised with SUPERSCRIPT ™ (BRL, Gaithersburg, MD, USA) . After conversion of the cDNA to double stranded (Gubler Sc Hoffman, Gene 25 263-269 (1983)) EcoRI linkers were ligated to the cDNA, and the product was digested with Notl . The £coRI-NotI cDΝA of 1.3 to 9 kb was isolated by gel electrophoresis, and a unidirectional library was constructed by ligation of the cDΝA to pBKCMV (Stratagene, San Diego, CA, USA) digested with the same enzymes. The library was electroporated into E. coli DH10B cells and divided in 24 pools of 8 x 10 4 clones. The plasmid DΝA from the pools was prepared by minialkaline lysis followed by LiCl precipitation (Sambrook et al . , loc. ci t) . Notl-linearised cDΝA was transcribed in vitro with T3 RΝA polymerase in the presence of the cap analogue m7GpppG (Sambrook et al . , loc. ci t) . The in vi tro transcribed RΝA (cRΝA) was concentrated to 4 mg/ml. EXAMPLE 2 Sequencing of the Rat vas deferens P 2χ Receptor cDNA The cDNA insert was sequenced the exonuclease method (Henikoff Meth . Enzymol . 155 156-164 (1987)) . The sequence is shown in Figure 1. EXAMPLE 3 Functional characterisation of the Rat vas deferens P 2χ Receptor cDNA in Oocytes 50 nl (200 ng) of RNA was injected into defolliculated Xenopus oocytes. After incubation for 2-6 days at 18°C, the oocytes were assayed for ATP-evoked currents by a two-electrode voltage clamp (GENECLAMP'") ,* one electrode is to hold the voltage constant (at -100 mV) , and the other is to measure the currents. A cDNA pool which showed ATP induced currents was subdivided to obtain a single clone (P 2X ) . Electrophysiological measurements were done at -100 mV, in a perfusion medium containing 96 mM NaCl, 2 mM KC1, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM Hepes pH 7.6, and 5 mM sodium pyruvate. For dose-response curves and suramin inhibition, oocytes were injected with 100 ng P 2X cRNA, and all recordings were performed at -60 mV, with Ba 2+ substituted for external Ca 2+ to prevent activation of endogenous Ca 2+ -activated Cl " currents. Microelectrodes (0.5-2 MΩ) were filled with 3M KCl. EXAMPLE 4 Functional characterisation of the Rat vas deferens P 2χ Receptor cDNA in HEK 293 Cells HEK 293 cells were transfected by the lipofectin method (Feigner et al . , Proc . Nat 'l . Acad. Sci . USA 84 7413-7417 (1987) ) with P 2X -plasmid. DNA concentration used was 1 mg/2 ml medium placed into a 35 mm petri dish containing four 11 mm diameter coverslips on which HEK cells were placed at 10,000 cells per coverslip. Cells were exposed to lipofectin/DNA for 6 h and recordings made 16 - 36 h later; 40 - 60% of cells from which recordings were made exhibited P 2X responses. Currents were recorded from HEK 293 cells using whole-cell recording methods and the AXOPATCH ' 200 amplifier (Axon Instruments) ,* patch pipettes (5 MΩ) contained (mM) Cs or K aspartate 140, NaCl 5, EGTA 11, HEPES 5. The external solution was (mM) NaCl 150, KCl 2, CaCl 2 2, MgCl 2 1, HEPES 5 and glucose 11; the pH and osmolarity of both solutions were maintained at 7.3 and 305 mosmol/1 respectively. All recordings performed at room temperature. Data acquisition and analysis were performed using PCLAMP ™ and AXOGRAPH ™ software (Axon Instruments) . Solutions for experiments examining calcium permeability of ATP currents in HEK cells contained (mM) : internal solution NaCl 150, HEPES 5, CaCl 2 0.5 and EGTA 5 (free calcium concentration about 5 nM) ; external sodium solution NaCl 150, glucose 11, histidine 5, CaCl 2 2; external calcium solution CaCl 2 115, glucose 11 and histidine 5. The pH and osmolarity of the solutions were 7.4 and 295 mosmol/1 respectively. For single channel measurements, a GENECLAMP ™ 500 amplifier and outside-out recording methods were used (Adelman et al . , Neuron 9 209-216 (1992)) . Wax-coated patch pipettes (5 - 10 MΩ) contained (mM) K-gluconate 115, HEPES 5, BAPTA 5 and MgCl 2 0.5, external solution was 96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2 , 1 mM MgCl 2 , 5 mM Hepes pH 7.6, and 5 mM sodium pyruvate. ATP was applied by U-tube typically for 1 s; data was sampled at 5 kHz in 2 s segments beginning 300 ms prior to onset of agonist (ATP) application and filtered at 1 kHz. EXAMPLE 5 Transfection of the Rat vas deferens P 2X Receptor cDNA into CHO and HEK293 Cells CHO cells were stably transfected by a method used for other ion channels (Claudio, Meth. Enzymol . 207 391-408 (1992)) . Transfection was confirmed by a) electro- physiological recording and b) radioligand binding. ATP and other agonists (up to 30 μM) caused rapidly desensitising inward currents in 14 of 14 CHO cells stably transfected, and had no effect in 45 of 45 non- transfected cells. [ 3 H] α/3methyleneATP binding was more than 600 cpm per million transfected cells with less than 80 cpm nonspecific binding. Stable transfection of HEK293 cells was also achieved. This was confirmed by electrophysiological recording. (ii) HUMAN P : , RECEPTOR The materials and methods used in the human P 2X receptor examples are set out below: In Vi tro translation In vi tro coupled transcription/ translation were performed using Promega's TNT Coupled reticulocyte lysate Systems with or without 2 μl of canine pancreatic microsomal membranes (Promega) . μg Circular pBKCMV-hP 2X (0.5 ug) was transcribed with the T3 RNA polymerase as described in the system manual in a 25 μl reaction for 2 h are 30°C. Synthesized proteins (5 μl) were analysed by SDS-PAGE and autoradiography. Differentiation of HL60 cells HL60 cells (human promyelocytes ATCC CCL240) were passaged twice weekly in RPMI-1640 supplemented with 25 mM HEPES, 2 mM Glutamax II, and 10% heat-inactivated fetal calf serum (GIBCO BRL) . For each experiment 33 x 10 s cells were resuspended at 2.5 x 10 5 cells/ml in medium containing either phorbol mystate acetate (100 nM) , 1.1% DMSO, or dibutyryl cAMP (200 uM) (SIGMA) for the indicated times. Northern blot analysis PolyA + RNAs were obtained from Clontech Laboratories Inc. (Palo Alto) except for the urinary bladder and HL60 mRNA which were prepared as described (Valera et al (1994) - supra) . Samples were quantified by measuring the O.D. at 260 nm, and by staining the membrane with methylene blue. The RNA were fractionated on a 1% agarose - 6% formaldehyde gel and electroblotted to a non-charged nylon membrane (BDH) . Prehybridisation at 68°C was performed for 6 hours in hybridisation buffer (50% formamide, 5X SSC, 2% blocking buffer (Boehringer Mannheim) , 0.1% laurolylsarcosine, 0.02% SDS) . Hybridisation was overnight at 68°C in fresh hybridisation buffer with a digoxigenin-UTP labelled riboprobe (100 ng/ml) corresponding to the entire hP 2X sequence. The membrane was washed at 68°C; twice in 2X SSC + 0.1% SDS, and twice in 0.1X SSC + 0.1% SDS. Chemiluminescent detection of hybridisation was carried at room temperature as follows: the membrane was rinsed 5 min in buffer Bl (0.1 M maleic acid, 0.15 M NaCl, pH 7.5), saturated for 1 hour in 1% blocking buffer (B2) , incubated 30 min with anti-digoxigenin-antibody alkaline phosphatase conjugated (750 u/ml, Boehringer Mannheim) diluted 1:15000 in B2, washed in Bl + 0.3% tween 20 (IX 5 min, IX 15 min, IX 1 h) , equilibrated for 5 min in buffer B3 (0.1 M Tris HCl pH 9.5, 0.1 M NaCl, 50 mM gCl 2 ) , incubated 45-60 sec in lumigen PPD (Boehringer Mannheim) diluted 1:100 in B3. The humid membrane was sealed in a plastic bag, incubated 15 min at 37°C, and exposed 15 to 20 min to Hyperfilm-ECL (Amersham) . P 2χ expression into oocytes Human urinary bladder P 2X cDNA, subcloned into the pBKCMV expression vector, was linearized with Notl, and transcribed in vitro with T3 polymerase in the presence of cap analogue m7G(5' )ppp(5' )G. Defolliculated Xenopus oocytes (Bertrand et al , Electrophysiology of neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes following nuclear injection of genes or cDNAs Meth Neurosci 4: 174-193 (1991)) were injected with 50 ng of human P 2X in vitro transcribed RNA, and incubated at 18°C for 2-6 days in the ND96 solution (mM) : NaCl96, KC12, MgCl 2 1, CaCl 2 2, sodium pyruvate 5, HEPES 5, ph 7.6 - 7.5, penicillin (10 U/ml), and streptomycin (10 μg/ml) . Electrophysiology Oocytes were placed in a 1 ml chamber and superfused at 2 - 3 ml/min with ND96 solution with 0.1 mM BaCl 2 replacing the 2 mM CaCl 2 to prevent activation of endogenous calcium-activated chloride currents (Barish, A transient calcium-dependent chloride current in the immature Xenopus oocytes J Physiol 342: 309-325 (1983)) . Currents were measured using a two- electrode voltage-clamp amplifier (Geneclamp Axon Instruments) at a holding potential of -60 mV. Microelectrodes were filled with 3 M KCl (0.5 - 2 MΩ) . Data were collected using PClamp software (Axon Instruments) . ATP and other purinoceptor agonists were applied by a U-tube perfusion system (Fenwick et al, A patch clamp study of bovine chromaffin cells and their sensitivity to acetylcholine J Physiol 331: 577-597 (1982)) placed close (200 - 500 μm) to the oocyte. Initial studies showed that reproducible responses (<10% variation in peak amplitude) could be obtained when ATP (at concentrations up to 1 mM) was applied to hP 2X injected oocytes for 5 s every 10 mins. Concentration response relationships to ATP and its analogs were determined by measuring the peak amplitude of responses to a 5 s application of agonist applied at 10 min intervals. Responses to agonists were normalized in each oocyte to the peak response evoked by 100 μM ATP; 100 μM ATP was usually applied at the beginning and at the end of an experiment to determine if there was any rundown of the response. No inward current was recorded in uninjected oocytes in response to application of purinoceptor agonists at the maximal concentration used (n = 3 for each agonist) . Antagonists were applied both in the superfusate and together with ATP in the U-tube solution. Antagonists were superfused for 5 - 10 min prior to the application of ATP. Data analysis Concentration response curves for purinoceptor agonists were fitted with a Hill slope of 1. Equi-effective concentrations i.e. concentration of agonist, giving 50% of the response to 100 μM ATP, (EEC 50 ) were determined from individual concentration response curves. For antagonists the concentration required to give 50% inhibition (IC50) of the response to 10 μM ATP (approximately 90% of peak response to ATP) were determined. Data are presented throughout as mean ± SEM for a given number of oocytes. Drugs Adenosine, adenosine 5' -monophosphate sodium salt (AMP), adenosine 5' -diphosphate sodium salt (ADP) , adenosine 5' -triphosphate magnesium salt (ATP), adenosine 5' -O- (-3-thiophosphate) tetralithiu salt (ATP-γ-S) , uridine 5' -triphosphate sodium salt (UTP), a,S-methylene ATP lithium salt [a, β, -meATP) , β ,γ-methylene-D-ATP sodium salt (D- / β,γ-meATP) , 2' -3' -0- (4-benzoylbenzol)ATP t e t rae thy1 amonium salt, (BzATP) , 4 , 4 ' - diisothiocyanatostilbene 2,2' -disulphonic acid, disodium salt (DIDS) were obtained from Sigma. 2-MethylthioATP tetra sodium salt (2MeSATP) , 2-chloro-ATP tetra sodium salt, and β-γ-methylene-l-ATP (1-jβ-γ-meATP) were obtained from RBI. Pyridoxal 5-phosphate monohydrate (Aldrich) , pi, p5-di [adenosine-5' ]pentaphosphate trilithium salt (AP5A) (Boehringer Mannheim) , pyridoxal phosphate 6- azophenyl 2', 4' -disulphonic acid (PPADS, gift of G. Lambrecht, University of Frankfurt) and suramin (Bayer) were tested. Drugs were prepared from frozen aliquots of stock solutions and diluted to give the required final concentration. EXAMPLE 6 Sequence and characteristics of hP 2χ from urinary bladder Isolation of human P 2χ cDNA Human urinary bladder tissue was obtained from a cystectomy for a bladder tumor. The patient showed no symptoms of bladder instability or urodynamic abnormalities. Only those portions, surrounding the tumor, which appeared macroscopically normal (Palea et al - supra) were used. Total RNA was isolated by guanidinium isothiocyanate and poly A + RNA was purified as described (Valera et al (1994) - supra) . Preparation of a cDNA library in λgtlO, random primer labelling of a rat smooth muscle P 2X probe (Valera et al (1994) - supra) , low stringency hybridisation screening and lambda phage DNA isolation were all done by standard protocols (Sambrook et al , Molecular Cloning, A Laboratory Manual, 2nd edn., Cold Spring Harbor Laboratory Press, New York (1989)) . Several independent phage isolates were examined and the cDNA insert from one was chosen for subcloning into Eco RI-Not I digested pBKCMV. This 2677 bp hP 2X cDNA was sequenced as described (Valera et al (1994) - supra) . The 2677 bp cDNA, hP 2X , contained a single long open reading frame which corresponds to a protein of 399 amino acids (Figure 4) . This amino acid sequence is highly homologous with that of the P 2X receptor, isolated from rat vas deferens (89% identity) . There are two regions of hydrophobicity near either end of the protein which are sufficiently long to traverse the membrane but there is no hydrophobic N-terminal leader sequence. All five potential sites for glycosylation and all ten cysteine residues in the central section of the protein are conserved. In vi tro translation of hP 2X RNA in the presence of microsomes produced a 60 kD product, whereas translation in the absence of microsomes produced the 45 kD peptide (Figure 6) . 45 kD is the computed molecular weight, suggesting that the additional 15 kD results from glycosylatio . Some human urinary bladder P 2X cDNA was used to transfect HEK293 cells. Stable transfection was confirmed by electrophysiological recording. EXAMPLE 7 Distribution of human urinary bladder P 2X mRNA The distribution of the human urinary bladder P 2X mRNA was examined by northern analysis. A single 2.6 kb mRNA species was observed in bladder, placenta, liver and adrenal gland (Figure 8) . In thymus, spleen, and lung samples, the 2.6 kb band plus additional higher molecular weight RNAs of 3.6 and 4.2 kb were seen. A smaller additional RNA species of 1.8 kb was observed in spleen and lung. No hybridisation was detected with brain mRNA. EXAMPLE 8 Induction of hP 2χ mRNA in HL60 cells A portion of the 3' -untranslated region had been previously deposited in the database (HSGS01701) as an expressed sequence tag for the differentiation of the human promyelocytic cell line, HL60 (Okubo unpublished) . We examined the induction of hP 2X mRNA in HL60 cells by Northern blot analysis (Figure 7) . HL60 cells can be differentiated into distinct lineages, depending on the inductant (Koeffler, Induction of Differentiation of Human Acute Myelogenous Leukemia Cells: Therapeutic Implications Blood 62: 709-721 (1983)) . Induction of macrophage-like characteristics with phorbol diesters or granulocytic differentiation with DMSO or dibutryl cAMP, each produced an increase in P 2X mRNA (Figure 7, lane 6) , HL60 RNA (lane 1-5) showed hybridisation of two bands (1.8 and 2.6 kb) and both of these were inducible. This contrasts with the bladder, where Northern analysis showed only a single RNA species (2.6 kb) (Figure 7, lane 6) . EXAMPLE 9 Pharmacological characterization of hP 2χ Application of ATP (30 nM - ImM) to oocytes injected with hP 2x receptor RNA evoked inward currents (Figures 9, 10 and 11) . Responses to low concentrations of ATP (30 - 300 nM) developed over 3-5 s. Higher concentrations of ATP (1 μM) evoked responses which peaked within 1 - 1.5 s and then declined during the continued application of ATP (40 - 60% of the peak amplitude after 5 s) . The current returned to control values on washout of ATP. The peak amplitude of the inward current evoked by ATP was concentration-dependent (Figures 9, 10 and 11) and could be fitted by a curve with a Hill slope of 1 with a EC 50 of 0.82 μM. When ATP (100 μM) was applied for 5 s every 10 min, reproducible inward currents were recorded. This is in contrast to the responses of the P 2X receptor clone from rat vas deferens where a second application of ATP (> 1 μM) applied 10 mins after the first, evoked an inward current that was -50% of the initial peak amplitude. Concentration-response curves were constructed for a number of other P2 purinoceptor agonists (Figures 9, 10 and 11) . 2meSATP, 2-chloro-ATP, α,j6-meATP and ADP were full agonists. BzATP, AP 5 A and ATP-γ-S produced maximal responses of about 65% of the maximal ATP response. The maximal responses to d and l-?,γ-meATP were not determined. Adenosine, AMP and UTP (100 μM) evoked small inward currents (2.3 ± 1.5, 6.08 ± 2, and 3.7 + 1.8% of the response to 100 μM ATP respectively) . The EEC 50 values and relative potencies of purinoceptor analogs are summarised in Table 1 below. Table 1 agonist EEC50(μM) relat ATP 0.82 1 2MeSATP 0.6 ± 0.1 1.36 2chloroATP 0.76 ± 0.1 1.08 AP5A 2 ± 0.2 0.41 , β-meATP 3.6 ± 1.6 0.23 BzATP 4.2 ± 2.2 0.20 ATP-γ-S 10.6 ± 3.8 0.077 ά, β , -meATP 24.1 ± 1.6 0.034 ADP 34.3 ± 16 0.024 EEC50: Equi-effective concentrations producing an inward current equivalent to 50% of the peak response to 100 μM ATP. EEC50 taken from individual fitted concentration response curves with a Hill slope of 1. EEC50 for ATP from mean data from all experiments, (n = 3-4) . EXAMPLE 10 Antagonist studies The P2-purinoceptor antagonist suramin (1 - 100 μM) shifted the concentration-response curve for ATP to the right. At 1 μM suramin the shift was almost parallel. The dissociation equilibrium constant (K B ) estimated from K B = 1/(DR-1) where DR is the dose ratio was 130 nM. With higher concentrations of suramin the inhibition did not appear to be competitive. Under the present experimental conditions this K B estimate is higher than those reported previously for suramin (pA2 5.9, Trezise et al , Br J Pharmacol 112: 282-288 (1994)) pK B 5.2, von Kugelgen et al , Interaction of adenine nucleotides, UTP and suramin in mouse vas deferens: suramin-sensitive and suramin- insensitive components in the contractile effect of ATP Naunyn Schmiedeberg' s Arch Pharmacol 342: 198-205 (1990) ) . The antagonism by suramin was fully reversed after 10 mins wash and indicates that the non-competitive antagonism at high concentrations is not due to irreversible binding of the antagonist to the receptor. The putative P 2χ purinoceptor antagonists PPADS, DIDS and pyridoxal 5 phosphate (Ziganshin et al , Selective antagonism by PPADS at P 2X purinoceptors in rabbit isolated blood vessels Br J Pharmacol 111: 923-929 (1994), Bultmann & Starke, Blockade by 4,4'- diisothiocyanatostilben-2,2' -disulphonate (DIDS) of P 2X purinoceptors in rat vas deferens Br J Pharmacol 112: 690-694 (1994), Trezise et al, Eur J Pharmacol 259: 295- 300 (1994)) inhibited inward currents evoked by 10 μM ATP (approximately EC 90 concentration) in a concentration dependent manner (Figures 12 and 13) . Suramin PPADS and DIDS were equally effective in inhibiting ATP evoked currents (IC 50 - 1 μM) . The IC 50 for P5P was - 20 μM. PPADS and P5P antagonism was readily reversible on washout. In contrast, inhibitory effects of DIDS (100 μM) were very slow to reverse on washout. (iii) RAT SUPERIOR CERVICAL GANGLION P χ RECEPTOR Example 11 Isolation and functional expression of a cDNA encoding a P 2χ receptor from rat superior cervical ganglion (referred to herein as clone 3) A 440 bp fragment was amplified by polymerase chainreac ion (PCR) from rat testis cDNA, using degenerate primers based on conserved nucleotide sequences within the rat vas deferens P 2X receptor cDNA and on the sequence of PC12 cDNA (Ehrlich H A (ed) PCR Technology MacMillan, Basingstoke (1989)) . The primers used are given below: Sense t G T/C G A A/G A/G T I T T/C I G G/C I T G G T G T/C C C 3' (SEQ ID NO 2) Antisense 5' G C A/G A A T/C C T A/G A A A/G T T A/G T/A A I C C 3' (SEQ ID NO 3) (wherein I = Inosine and "T/C" indicates that either T or C is present at the position indicated (this applies mutatis mutandis to the other alternatives given) . The cloned PCR fragment was labelled and used as a hybridization probe for screening a rat testis cDNA bank in λZAP. One recombinant phage was positive, and its insert was excised and transferred to a plasmid (#432) . This cDNA was 1500 bp with a single EcoRl site (at position 1000, still in the open reading frame) . The 5' end of the cDNA was too short to encode the entire N terminus. Internal primers specific to the new sequence were made and the tissue distribution was tested by PCR. The candidate was present in mRNA prepared from phaeochromocytoma (PC12) cells, intestine and superior cervical ganglion (scg) . The hybridization probe was therefore used to screen a rat scg cDNA bank in λgtlO. From 30 initial positives, 20 pure phage DNA stocks were prepared; 19 were various portions of the candidate sequence, and the insert from one was transferred to plasmid (p457) and sequenced. The insert appeared to be a full length cDNA; it has a single open reading frame of 388 amino acids (Fig. 2) . The insert from p457 was subcloned into pcDNA3 (p464) and used to transfect human embryonic kidney (HEK293) cells. The functional characterisation of the clone illustrated in Fig 2 (referred to herein as clone 3) was carried out by electrical recordings from transfected HEK293 cells and from oocytes injected with the in vi tro transcribed RNA, as described in Example 4 for the rat vas deferens P 2X receptor. Table A summarizes the main properties of clone 3 as compared to those of rat vas/human bladder cDNA clone, and the PC12 cDNA clone (provided by David Julius and Tony Brake of the University of California at San Francisco) . TABLE A Functional Properties of 3 cloned P 2χ Receptors kinetics bladder clone 3 PC12 desensitization very strong very little very little rundown profound very little very little ionic permeability monovalent no differences no differences no differences 10 divalent (Ca ++ ) high permeability high permeability high permeability Ca ++ block none intermediate very strong agonist prof ile ATP 0 . 7 μM 11 μM 8 μM 15 or , jS-me TP 3 μM >>100 mM >>100 μM antagonist profile suramin 1 μM < 40% block 6 μM PPADS 1 μM < 30% block 1 μM 20 P-5-P 6 μM < 40% block 6 μM DIDS 1 μM > 100 μM The main functional properties of clone 3 are as follows, (a) The currents evoked by ATP show little or no decline during applications of several seconds; that is, there is little desensitisation (Fig. 14) . (b) The relative permeabilities of the ionic pore to sodium, potassium, cesium, tetraethylammonium and to calcium are not different to those observed for the rat vas deferens/human bladder or the PC12 forms of the receptor, (c) Extracellular calcium (30 mM) inhibits the inward current through the P 2X receptor channel of the PC12 form whereas it does not block current through the rat vas deferens/human bladder form; clone 3 is intermediate in sensitivity. (d) The effectiveness of agonists that are structurally related to ATP is the same as that found for the PC12 form; most notably, αjSmethylene ATP has little or no agonist action (Fig. 14) . (e) Currents activated by ATP at the clone 3 receptor were much less sensitive to antagonism by suramin., pyridoxal 5'-phosphate and pyridoxal-6-azophenyl-2' ,4' -disulphonic acid (PPADS) than were similar current mediated by the other two forms (rat vas deferens/human bladder; PC12) (Fig. 15) . 40 (iv) RAT DORSAL ROOT GANGLION P.,- RECEPTOR Example 12 Isolation of a cDNA encoding a P 2χ receptor from a rat dorsal root ganglion By using PCR with the same primers as used in Example 11 above, but using different cDNA sources, further P 2X family members can be found. Using this method, rat dorsal root ganglion P 2X receptor cDNA was isolated. Fig. IB shows the cDNA sequence of this clone (referred to herein as clone 6) , together with the putative amino acid sequence. The portions underlined in this figure correspond to the PCR primers initially used. A similar procedure to that described in Example 11 was then used to isolate the full length cDNA. SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: (A) NAME: GLAXO GROUP LIMITED (B) STREET: GLAXO HOUSE. BERKELEY AVENUE (C) CITY: GREENFORD (D) STATE: MIDDLESEX (E) COUNTRY: UNITED KINGDOM (F) POSTAL CODE (ZIP): UB6 ONN (ii) TITLE OF INVENTION: DNA AND PROTEIN SEQUENCES (iii) NUMBER OF SEQUENCES: 11 (iv) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Patentln Release #1.0. Version #1.30 (EPO) (2) INFORMATION FOR SEQ ID NO: 1: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 33 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1: GAGAGAGAGA GCGGCCGCTT 1111111111 TIT 33 (2) INFORMATION FOR SEQ ID NO: 2: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 23 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (lx) FEATURE: (A) NAME/KEY: modified base (B) LOCATIONS (D) OTHER INFORMATION:/mod_base= OTHER /note= "T or C" (lx) FEATURE: (A) NAME/KEY- modified base (B) LOCATION:6 (D) OTHER INFORMATIO :/mod_base= OTHER /note= "A or G" (lx) FEATURE: (A) NAME/KEY: modified base (B) LOCATION-7 (D) OTHER INFORMATION:/mod_base= OTHER /note= "A or G" (lx) FEATURE: (A) NAME/KEY: modified base (B) LOCATIO :9 (D) OTHER INFORMATION:/mod_base= l (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATION:11 (D) OTHER INFORMATION:/mod_base= OTHER /note= "T or C" (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATION:12 (D) OTHER INFORMATION:/mod_base= i (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATION:14 (D) OTHER INFORMATION:/mod_base= OTHER /note= "G or C" (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATION:15 (D) OTHER INFORMATION:/mod_base= l (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATION:21 (D) OTHER INFORMATION:/mod_base= OTHER /note= "T or C" (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2: TGNGANNTNT NNGNNTGGTG NCC 23 (2) INFORMATION FOR SEQ ID NO: 3: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 20 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATIONS (D) OTHER INFORMATION:/mod_base= OTHER /note= "A or G" (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATION:6 (D) OTHER INFORMATION:/mod_base= OTHER /note= "T or C" (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATIONS (D) OTHER INFORMATION:/mod_base= OTHER /note= "A or G" (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATION:12 (D) OTHER INFORMATION:/mod_base= OTHER /note= "A or G" (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATION:15 (D) OTHER INFORMATION:/mod_base= OTHER /note= "A or G" (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATION:16 (D) OTHER INFORMATION:/mod_base= OTHER /note= "T or A" (ix) FEATURE: (A) NAME/KEY: modified base (B) LOCATION:18 (D) OTHER INFORMATION:/mod base= i (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3: GCNAANCTNA ANTTNNANCC 20 (2) INFORMATION FOR SEQ ID NO: 4: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1837 base pairs (B) TYPE: nucleic acid (0 STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: rat P2x from vas deferens (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:210..1406 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4: GCCAAAAGCT GTTCTGATCA CCCAGGGTTT TTCCTCCCAA CCCAGACCCC ACCATCGAAC 60 CTCCAACTCT GGTCCCACCT AGCCTGCTCT GTCCTTAAGG GGCCGGGAAG CCCCAGTCAC 120 TCCACTGCTA TTGTAGATGC AGATGGTGGC CTGCCCTTGA CCATAGAGGC CGTGTGGGGT 180 GTTCATCTCT GAGCCCCTTC TGGCCCACC ATG GCT CGG CGG CTG CAA GAT GAG 233 Met Ala Arg Arg Leu Gin Asp Glu 1 5 CTG TCA GCC πC πC mr GAA TAT GAC ACT CCC CGG ATG GTG CTG GTA 281 Leu Ser Ala Phe Phe Phe Glu Tyr Asp Thr Pro Arg Met Val Leu Val 10 15 20 CGA AAC AAG AAG GTG GGA GTC AH TTC CGT CTG ATC CAG TTG GTG GTT 329 Arg Asn Lys Lys Val Gly Val He Phe Arg Leu He Gin Leu Val Val 25 30 35 40 CTG GTC TAC GTC ATT GGG TGG GTG TTT GTC TAT GAA AAA GGA TAC CAG 377 Leu Val Tyr Val He Gly Trp Val Phe Val Tyr Glu Lys Gly Tyr Gin 45 50 55 ACC TCA AGT GAC CTC ATC AGC AGT GTG TCC GTG AAG CTC AAG GGC TTG 425 Thr Ser Ser Asp Leu He Ser Ser Val Ser Val Lys Leu Lys Gly Leu 60 65 70 GCT GTG ACC CAG CTC CAG GGC CTG GGA CCC CAG GTC TGG GAC GTG GCT 473 Ala Val Thr Gin Leu Gin Gly Leu Gly Pro Gin Val Trp Asp Val Ala 75 80 85 GAC TAT GTC πC CCA GCA CAC GGG GAC AGC TCC TTT GTA GTT ATG ACC 521 Asp Tyr Val Phe Pro Ala His Gly Asp Ser Ser Phe Val Val Met Thr 90 95 100 AAC πC ATC GTG ACC CCT CAG CAG ACT CAA GGC CAT TGT GCA GAG AAC 569 Asn Phe He Val Thr Pro Gin Gin Thr Gin Gly His Cys Ala Glu Asn 105 110 115 120 CCA GAA GGT GGC ATA TGC CAG GAT GAC AGT GGC TGC ACT CCA GGA AAA 617 Pro Glu Gly Gly He Cys Gin Asp Asp Ser Gly Cys Thr Pro Gly Lys 125 130 135 GCA GAA AGG AAA GCC CAA GGT ATT CGC ACA GGC AAC TGT GTG CCC TTC 665 Ala Glu Arg Lys Ala Gin Gly He Arg Thr Gly Asn Cys Val Pro Phe 140 145 150 AAT GGC ACT GTG AAG ACA TGT GAG ATC TTT GGT TGG TGT CCT GTA GAG 713 Asn Gly Thr Val Lys Thr Cys Glu He Phe Gly Trp Cys Pro Val Glu 155 160 165 GTG GAT GAC AAG ATC CCA AGC CCT GCT CTT CTT CGT GAG GCT GAG AAC 761 Val Asp Asp Lys He Pro Ser Pro Ala Leu Leu Arg Glu Ala Glu Asn 170 175 180 TTC ACC CTC πC ATC AAA AAC AGC ATC AGC TTT CCA CGC TTC AAG GTC 809 Phe Thr Leu Phe He Lys Asn Ser He Ser Phe Pro Arg Phe Lys Val 185 190 195 200 AAC AGG CGC AAC CTG GTA GAG GAG GTG AAC GGC ACC TAC ATG AAG AAG 857 Asn Arg Arg Asn Leu Val Glu Glu Val Asn Gly Thr Tyr Met Lys Lys 205 210 215 TGC CTC TAT CAC AAG ATT CAA CAC CCC CTG TGC CCA GTC TTC AAC CTT 905 Cys Leu Tyr His Lys He Gin His Pro Leu Cys Pro Val Phe Asn Leu 220 225 230 GGC TAT GTG GTG CGA GAG TCA GGC CAG GAC TTC CGC AGC CTT GCT GAG 953 Gly Tyr Val Val Arg Glu Ser Gly Gin Asp Phe Arg Ser Leu Ala Glu 235 240 245 AAG GGT GGG GTG GTT GGT ATC ACC ATT GAC TGG AAG TGT GAT CTG GAC 1001 Lys Gly Gly Val Val Gly He Thr He Asp Trp Lys Cys Asp Leu Asp 250 255 260 TGG CAC GTT CGG CAC TGC AAA CCC ATC TAC CAG TTC CAC GGA CTG TAT 1049 Trp His Val Arg His Cys Lys Pro He Tyr Gin Phe His Gly Leu Tyr 265 270 275 280 GGG GAG AAG AAC CTG TCT CCA GGC TTC AAC TTC AGA TTT GCC AGG CAT 1097 Gly Glu Lys Asn Leu Ser Pro Gly Phe Asn Phe Arg Phe Ala Arg His 285 290 295 πC GTG CAG AAT GGG ACA AAC CGT CGT CAC CTC TTC AAG GTG TTT GGG 1145 Phe Val Gin Asn Gly Thr Asn Arg Arg His Leu Phe Lys Val Phe Gly 300 305 310 ATT CAC TTT GAT ATC CTT GTG GAT GGC AAG GCT GGG AAG TTT GAC ATC 1193 He His Phe Asp He Leu Val Asp Gly Lys Ala Gly Lys Phe Asp He 315 320 325 ATC CCT ACT ATG ACT ACT ATC GGT TCT GGG ATT GGC ATC TTT GGA GTG 1241 He Pro Thr Met Thr Thr He Gly Ser Gly He Gly He Phe Gly Val 330 335 340 GCC ACA GTG CH TGT GAT CTC TTA TTG CTC CAC ATC CTG CCT AAG AGG 1289 Ala Thr Val Leu Cys Asp Leu Leu Leu Leu His He Leu Pro Lys Arg 345 350 355 360 CAC TAC TAC AAG CAG AAG AAG TTC AAA TAT GCC GAG GAC ATG GGG CCG 1337 His Tyr Tyr Lys Gin Lys Lys Phe Lys Tyr Ala Glu Asp Met Gly Pro 365 370 375 GGA GAG GGT GAA CAT GAC CCC GTG GCC ACC AGC TCC ACT CTG GGC CTG 1385 Gly Glu Gly Glu His Aso Pro Val Ala Thr Ser Ser Thr Leu Gly Leu 380 385 390 CAG GAG AAC ATG AGG ACC TCC TGACCTTAGT CTTGAGATCC GGACTTGACG 1436 Gin Glu Asn Met Arg Thr Ser 395 CAGTGTGTGG CTTCCGGCAA GGGCTGATGG CTTTGAGCCA GGGCAGAGGG CATTCCCAGA 1496 GGCTTTCCTG CAAGGCAGAC ACCAGTGGCC CTCTGGTTCA GCATGAAGAC AGGCAAGACT 1556 TTGGATTTCA GAGCTCTGGT TTCAGTTCCA CATGTCCCTT CCTGAGGGAT GCCTCCTCCA 1616 GTTTTCACCA ATTTGGGTTC ATATGGCTGG GCCCCTCACA CATCTATACT CTAGCTTTGT 1676 GCTTAAGGCT CAGGCTGTCA TTGTCTTTCC CACAGCCTTA CCTGCCTAGA TπGGGCTCT 1736 TCCACATGGT AGCCACTAGC CAGATGTGTC AGTTTGAACT TTAATTAAAA TATAATAAAA 1796 AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA A 1837 (2) INFORMATION FOR SEQ ID NO: 5: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: Drotein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5: Met Ala Arg Arg Leu Gin Asp Glu Leu Ser Ala Phe Phe Phe Glu Tyr 1 5 10 15 Asp Thr Pro Arg Met Val Leu Val Arg Asn Lys Lys Val Gly Val He 20 25 30 Phe Arg Leu He Gin Leu Val Val Leu Val Tyr Val He Gly Trp Val 35 40 45 Phe Val Tyr Glu Lys Gly Tyr Gin Thr Ser Ser Asp Leu He Ser Ser 50 55 60 Val Ser Val Lys Leu Lys Gly Leu Ala Val Thr Gin Leu Gin Gly Leu 65 70 _ 75 80 Gly Pro Gin Val Trp Asp Val Ala Asp Tyr Val Phe Pro Ala His Gly 85 90 95 Asp Ser Ser Phe Val Val Met Thr Asn Phe He Val Thr Pro Gin Gin 100 105 110 Thr Gin Gly His Cys Ala Glu Asn Pro Glu Gly Gly He Cys Gin Asp 115 120 125 Asp Ser Gly Cys Thr Pro Gly Lys Ala Glu Arg Lys Ala Gin Gly He 130 135 140 Arg Thr Gly Asn Cys Val Pro Phe Asn Gly Thr Val Lys Thr Cys Glu 145 150 155 160 He Phe Gly Trp Cys Pro Val Glu Val Asp Asp Lys He Pro Ser Pro 165 170 175 Ala Leu Leu Arg Glu Ala Glu Asn Phe Thr Leu Phe He Lys Asn Ser 180 185 190 He Ser Phe Pro Arg Phe Lys Val Asn Arg Arg Asn Leu Val Glu Glu 195 200 205 Val Asn Gly Thr Tyr Met Lys Lys Cys Leu Tyr His Lys He Gin His 210 215 220 Pro Leu Cys Pro Val Phe Asn Leu Gly Tyr Val Val Arg Glu Ser Gly 225 230 235 240 Gin Asp Phe Arg Ser Leu Ala Glu Lys Gly Gly Val Val Gly He Thr 245 250 255 He Aso Trp Lys Cys Asp Leu Asp Trp His Val Arg His Cys Lys Pro 260 265 270 He Tyr Gin Phe His Gly Leu Tyr Gly Glu Lys Asn Leu Ser Pro Gly 275 280 285 Phe Asn Phe Arg Phe Ala Arg His Phe Val Gin Asn Gly Thr Asn Arg 290 295 300 Arg His Leu Phe Lys Val Phe Gly He His Phe Asp He Leu Val Asp 305 310 315 320 Gly Lys Ala Gly Lys Phe Asp He He Pro Thr Met Thr Thr He Gly 325 330 335 Ser Gly He Gly He Phe Gly Val Ala Thr Val Leu Cys Asp Leu Leu 340 345 350 Leu Leu His He Leu Pro Lys Arg His Tyr Tyr Lys Gin Lys Lys Phe 355 360 365 Lys Tyr Ala Glu Asp Met Gly Pro Gly Glu Gly Glu His Asp Pro Val 370 375 380 Ala Thr Ser Ser Thr Leu Gly Leu Gin Glu Asn Met Arg Thr Ser 385 390 395 (2) INFORMATION FOR SEQ ID NO: 6: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1997 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vii) IMMEDIATE SOURCE: (B) CLONE: rat P2x clone 3 (i ) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:101..1264 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6: CGCAGCGAGC CTGCCGGAGC TGGTGGGTGG AGCTACGACC GGGAGCCGAC GGTGGCGAGG 60 GGACCCACAG TGTCCAAGGC GCGGAGCGGT CGGCGGAGCC ATG GCG GGC TGC TGC 115 Met Ala Gly Cys Cys 400 TCC GTG CTC GGG TCC TTC CTG TTC GAG TAC GAC ACG CCG CGC ATC GTG 163 Ser Val Leu Gly Ser Phe Leu Phe Glu Tyr Asp Thr Pro Arg He Val 405 410 415 420 CTC ATC CGC AGC CGT AAA GTG GGG CTC ATG AAC CGC GCG GTG CAG CTG 211 Leu He Arg Ser Arg Lys Val Gly Leu Met Asn Arg Ala Val Gin Leu 425 430 435 CTC ATC CTG GCT TAC GTC ATC GGG TGG GTG TTC GTG TGG GAA AAG GGC 259 Leu He Leu Ala Tyr Val He Gly Trp Val Phe Val Trp Glu Lys Gly 440 445 450 TAC CAG GAA ACG GAC TCC GTG GTC AGC TCG GTG ACA ACC AAA GCC AAA 307 Tyr Gin Glu Thr Asp Ser Val Val Ser Ser Val Thr Thr Lys Ala Lys 455 460 465 GGT GTG GCT GTG ACC AAC ACC TCT CAG CTT GGA TTC CGG ATC TGG GAC 355 Gly Val Ala Val Thr Asn Thr Ser Gin Leu Gly Phe Arg He Trp Asp 470 475 480 GTG GCG GAC TAT GTG AH CCA GCT CAG GAG GAA AAC TCC CTC TTC ATT 403 Val Ala Asp Tyr Val He Pro Ala Gin Glu Glu Asn Ser Leu Phe He 485 490 495 500 ATG ACC AAC ATG ATT GTC ACC GTG AAC CAG ACA CAG AGC ACC TGT CCA 451 Met Thr Asn Met He Val Thr Val Asn Gin Thr Gin Ser Thr Cys Pro 505 510 515 GAG ATT CCT GAT AAG ACC AGC ATT TGT AAT TCA GAC GCC GAC TGC ACT 499 Glu He Pro Asp Lys Thr Ser He Cys Asn Ser Asp Ala Asp Cys Thr 520 525 530 CCT GGC TCC GTG GAC ACC CAC AGC AGT GGA GTT GCG ACT GGA AGA TGT 547 Pro Gly Ser Val Asp Thr His Ser Ser Gly Val Ala Thr Gly Arg Cys 535 540 545 GH CCT πC AAT GAG TCT GTG AAG ACC TGT GAG GTG GCT GCA TGG TGC 595 Val Pro Phe Asn Glu Ser Val Lys Thr Cys Glu Val Ala Ala Trp Cys 550 555 560 CCG GTG GAG AAC GAC Gπ GGC GTG CCA ACG CCG GCT πC πA AAG GCT 643 Pro Val Glu Asn Asp Val Gly Val Pro Thr Pro Ala Phe Leu Lys Ala 565 570 575 580 GCA GAA AAC πC ACC CTC πG GTA AAG AAC AAC ATC TGG TAC CCC AAG 691 Ala Glu Asn Phe Thr Leu Leu Val Lys Asn Asn He Trp Tyr Pro Lys 585 590 595 TTT AAC πC AGC AAG AGG AAC ATC CTC CCC AAC ATC ACC ACG TCC TAC 739 Phe Asn Phe Ser Lys Arg Asn He Leu Pro Asn He Thr Thr Ser Tyr 600 605 610 CTC AAA TCG TGC Aπ TAC AAT GCT CAA ACG GAT CCC TTC TGC CCC ATA 787 Leu Lys Ser Cys He Tyr Asn Ala Gin Thr Asp Pro Phe Cys Pro He 615 620 625 πC CGT Cπ GGC ACA ATC GTG GGG GAC GCG GGA CAT AGC πC CAG GAG 835 Phe Arg Leu Gly Thr He Val Gly Asp Ala Gly His Ser Phe Gin Glu 630 635 640 ATG GCA Gπ GAG GGA GGC ATC ATG GGT ATC CAG ATC AAG TGG GAC TGC 883 Met Ala Val Glu Gly Gly He Met Gly He Gin He Lys Trp Asp Cys 645 650 655 660 AAC CTG GAT AGA GCC GCC TCC Cπ TGC CTG CCC AGA TAT TCC πC CGG 931 Asn Leu Asp Arg Ala Ala Ser Leu Cys Leu Pro Arg Tyr Ser Phe Arg 665 670 675 CGC CTG GAC ACC CGG GAC CTG GAA CAC AAT GTG TCT CCT GGC TAC AAT 979 Arg Leu Asp Thr Arg ASD Leu Glu His Asn Val Ser Pro Gly Tyr Asn 680 685 690 πC AGG πT GCC AAG TAC TAC AGG GAC CTG GCC GGC AAA GAG CAG CGC 1027 Phe Arg Phe Ala Lys Tyr Tyr Arg Asp Leu Ala Gly Lys Glu Gin Arg 695 700 705 ACA CTC ACC AAG GCG TAC GGC ATC CGC TTT GAC ATC ATC GTG TTT GGA 1075 Thr Leu Thr Lys Ala Tyr Gly He Arg Phe Asp He He Val Phe Gly 710 715 720 AAG GCT GGG AAG Tπ GAC ATC ATC CCT ACC ATG ATC AAC Gπ GGC TCT 1123 Lys Ala Gly Lys Phe Asp He He Pro Thr Met He Asn Val Gly Ser 725 730 735 740 GGC πG GCG CTC CTC GGG GTG GCG ACG GTG CTC TGT GAC GTC ATA GTC 1171 Gly Leu Ala Leu Leu Gly Val Ala Thr Val Leu Cys Asp Val He Val 745 750 755 CTC TAC TGC ATG AAG AAG AAA TAC TAC TAC CGG GAC AAG AAA TAT AAG 1219 Leu Tyr Cys Met Lys Lys Lys Tyr Tyr Tyr Arg Asp Lys Lys Tyr Lys 760 765 770 TAT GTG GAA GAC TAC GAG CAG GGT Cπ TCG GGG GAG ATG AAC CAG 1264 Tyr Val Glu Asp Tyr Glu Gin Gly Leu Ser Gly Glu Met Asn Gin 775 780 785 TGACGCCTAA AGπACAπT CCACCCCGCT CAGCCCGCGA AGCAGAAAGA TGGGGAGAGA 1324 TGGCTACTGC GTCTGTCACT CTAGAGAAAG CTCCAGAGπ TCAGCTCAGT TCTCCACTCC 1384 ACAAATACTC AGGGπGCCA AGCACATCπ GπGGAGCCC GGCTCπGCT CTGCTGCTCA 1444 GATGGGCπC CAGATACAAG AATCCTCCTG CπCTGCCTC TAGGAATGCT GGGATCAAAC 1504 ATGTCACπG CAATGCCCAT πCCCATGGG GAGTTTGGCA TππTACAT πTACCCπT 1564 CCTTTTGTAT ACATCTAAGG CTGCCCTCAG ACGCAAGACG πcπCCACC CTATACACCC 1624 TΠTAATCTC ACTGTGTGTG GGAGGGGGGT CGπTGCACA CGACGCACGG TGGATGTCTG 1684 GTGTGCTGπ GGCTGGGCCA CCTGTGGCπ ATACAGTGTG AGCGTATGGA GGTAGGAAGG 1744 GTCTGAGAGC AGAGACACTG CTGTGGCπA CGGACAGGCC CAGGCTCTGT CCACGCACπ 1804 TATπCTAAG GAAGGAGGCT CTCTCAGGTG CTGTCAGCAG GCCTGGGACA CCAπCCTCT 1864 TCCCTATAAT CAGAGAAGπ GTCCπGTAG CAAAGGCAGG GπAGCπiT CCTπTATAA 1924 GGGCTGTGπ GAAATGACCT AGGACCAAAC AπAAAAGAA AAAAAAAAAA 1984 AAAAAAAAAA AAA 1997 (2) INFORMATION FOR SEQ ID NO: 7 : (i ) SEQUENCE CHARACTERISTICS: (A) LENGTH: 388 ammo acids (B) TYPE: amino acid (D) TOPOLOGY: l inear (i i ) MOLECULE TYPE: protein (xi ) SEQUENCE DESCRIPTION: SEQ ID NO: 7: Met Ala Gly Cys Cys Ser Val Leu Gly Ser Phe Leu Phe Glu Tyr Asp 1 5 10 15 Thr Pro Arg He Val Leu He Arg Ser Arg Lys Val Gly Leu Met Asn 20 25 30 Arg Ala Val Gin Leu Leu He Leu Ala Tyr Val He Gly Trp Val Phe 35 40 45 Val Trp Glu Lys Gly Tyr Gin Glu Thr Asp Ser Val Val Ser Ser Val 50 55 60 Thr Thr Lys Ala Lys Gly Val Ala Val Thr Asn Thr Ser Gin Leu Gly 65 70 75 80 Phe Arg He Trp Asp Val Ala Asp Tyr Val He Pro Ala Gin Glu Glu 85 90 95 Asn Ser Leu Phe He Met Thr Asn Met He Val Thr Val Asn Gin Thr 100 105 110 Gin Ser Thr Cys Pro Glu He Pro Asp Lys Thr Ser He Cys Asn Ser 115 120 125 Asp Ala Asp Cys Thr Pro Gly Ser Val Asp Thr His Ser Ser Gly Val 130 135 140 Ala Thr Gly Arg Cys Val Pro Phe Asn Glu Ser Val Lys Thr Cys Glu 145 150 155 160 Val Ala Ala Trp Cys Pro Val Glu Asn Asp Val Gly Val Pro Thr Pro 165 170 175 Ala Phe Leu Lys Ala Ala Glu Asn Phe Thr Leu Leu Val Lys Asn Asn 180 185 190 He Trp Tyr Pro Lys Phe Asn Phe Ser Lys Arg Asn He Leu Pro Asn 195 200 205 He Thr Thr Ser Tyr Leu Lys Ser Cys He Tyr Asn Ala Gin Thr Asp 210 215 220 Pro Phe Cys Pro He Phe Arg Leu Gly Thr He Val Gly Asp Ala Gly 225 230 235 240 His Ser Phe Gin Glu Met Ala Val Glu Gly Gly He Met Gly He Gin 245 250 255 He Lys Trp Asp Cys Asn Leu Asp Arg Ala Ala Ser Leu Cys Leu Pro 260 ■ 265 270 Arg Tyr Ser Phe Arg Arg Leu Asp Thr Arg Asp Leu Glu His Asn Val 275 280 285 Ser Pro Gly Tyr Asn Phe Arg Phe Ala Lys Tyr Tyr Arg Asp Leu Ala 290 295 300 Gly Lys Glu Gin Arg Thr Leu Thr Lys Ala Tyr Gly He Arg Phe Asp 305 310 315 320 He He Val Phe Gly Lys Ala Gly Lys Phe Asp He He Pro Thr Met 325 330 335 He Asn Val Gly Ser Gly Leu Ala Leu Leu Gly Val Ala Thr Val Leu 340 345 350 Cys Asp Val He Val Leu Tyr Cys Met Lys Lys Lys Tyr Tyr Tyr Arg 355 360 365 Asp Lys Lys Tyr Lys Tyr Val Glu Asp Tyr Glu Gin Gly Leu Ser Gly 370 375 380 Glu Met Asn Gin 385 (2) INFORMATION FOR SEQ ID NO: 8 (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1753 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (n) MOLECULE TYPE: cDNA (vπ) IMMEDIATE SOURCE. (B) CLONE: rat P2x clone 6 (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:163..1353 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8: CACTGGGCTA CAGπGCCTG GCπACAGGA ACTGGCTCπ πCCTCAAGC CTCAπAAGC 60 AGCCCACTCC AGπcπGAT CTTTGTCTCC CAGTCCTGAA GTCCTTTCTC TCCTTAGGCT 120 GCATCCACAG CCCπCTAAG TGGCTGTGAG CAGTTTCTCA GT ATG AAC TGT ATA 174 Met Asn Cys He 390 TCA GAC TTC πC ACC TAC GAG ACT ACC AAG TCG GTG Gπ GTG AAG AGC 222 Ser Asp Phe Phe Thr Tyr Glu Thr Thr Lys Ser Val Val Val Lys Ser 395 400 405 TGG ACC Aπ GGG ATC ATC AAC CGA GCC GTC CAG CTG CTG Aπ ATC TCC 270 Trp Thr He Gly He He Asn Arg Ala Val Gin Leu Leu He He Ser 410 415 420 TAC TTT GTG GGG TGG Gπ πC πG CAT GAG AAG GCC TAC CAA GTG AGG 318 Tyr Phe Val Gly Trp Val Phe Leu His Glu Lys Ala Tyr Gin Val Arg 425 430 435 440 GAC ACC GCC Aπ GAG TCC TCA GTA Gπ ACA AAG GTG AAA GGC πC GGG 366 Asp Thr Ala He Glu Ser Ser Val Val Thr Lys Val Lys Gly Phe Gly 445 450 455 CGC TAT GCC AAC AGA GTC ATG GAC GTG TCG GAT TAT GTG ACC CCA CCC 414 Arg Tyr Ala Asn Arg Val Met Asp Val Ser Asp Tyr Val Thr Pro Pro 460 465 470 CAG GGC ACC TCT GTC TTT GTC ATC ATC ACC AAA ATG ATC Gπ ACT GAA 462 Gin Gly Thr Ser Val Phe Val He He Thr Lys Met He Val Thr Glu 475 480 485 AAT CAA ATG CAA GGA πC TGT CCA GAG AAT GAA GAG AAG TAC CGC TGT 510 Asn Gin Met Gin Gly Phe Cys Pro Glu Asn Glu Glu Lys Tyr Arg Cys 490 495 500 GTG TCT GAC AGC CAG TGT GGG CCT GAA CGC πC CCA GGT GGG GGG ATC 558 Val Ser Asp Ser Gin Cys Gly Pro Glu Arg Phe Pro Gly Gly Gly He 505 510 515 520 CTC ACC GGC CGC TGC GTG AAC TAC AGC TCT Gπ CTC CGG ACC TGT GAG 606 Leu Thr Gly Arg Cys Val Asn Tyr Ser Ser Val Leu Arg Thr Cys Glu 525 530 535 ATC CAG GGC TGG TGC CCC ACT GAG GTG GAC ACC GTG GAG ATG CCT ATC 654 He Gin Gly Trp Cys Pro Thr Glu Val Asp Thr Val Glu Met Pro He 540 545 550 ATG ATG GAG GCT GAG AAC πC ACC Aπ πc ATC AAG AAC AGC ATC CGT 702 Met Met Glu Ala Glu Asn Phe Thr He Phe He Lys Asn Ser He Arg 555 560 565 πc CCT CTC πc AAC πr GAG AAG GGA AAC CTC CTG CCT AAC CTC ACC 750 Phe Pro Leu Phe Asn Phe Glu Lys Gly Asn Leu Leu Pro Asn Leu Thr 570 575 580 GAC AAG GAC ATA AAG AGG TGC CGC πC CAC CCT GAA AAG GCC CCA TTT 798 Asp Lys Asp He Lys Arg Cys Arg Phe His Pro Glu Lys Ala Pro Phe 585 590 595 600 TGC CCC ATC πG AGG GTA GGG GAT GTG Gπ AAG πT GCT GGA CAG GAT 846 Cys Pro He Leu Arg Val Gly Asp Val Val Lys Phe Ala Gly Gin Asp 605 610 615 TTT GCC AAG CTG GCC CGC ACG GGT GGC Gπ CTG GGT Aπ AAG ATC GGC 894 Phe Ala Lys Leu Ala Arg Thr Gly Gly Val Leu Gly He Lys He Gly 620 625 630 TGG GTG TGC GAT CTA GAC AAG GCC TGG GAC CAG TGC ATC CCT AAA TAT 942 Trp Val Cys Asp Leu Asp Lys Ala Trp Asp Gin Cys He Pro Lys Tyr 635 640 645 TCC πC ACT CGG CTG GAT GGA Gπ TCT GAG AAA AGC AGT Gπ TCC CCT 990 Ser Phe Thr Arg Leu Asp Gly Val Ser Glu Lys Ser Ser Val Ser Pro 650 655 660 GGC TAC AAC πc AGG πT GCC AAA TAC TAT AAG ATG GAG AAC GGC AGC 1038 Gly Tyr Asn Phe Arg Phe Ala Lys Tyr Tyr Lys Met Glu Asn Gly Ser 665 670 675 680 GAG TAC CGC ACA CTC CTG AAG GCT Tπ GGC ATC CGC TTT GAT GTG CTG 1086 Glu Tyr Arg Thr Leu Leu Lys Ala Phe Gly He Arg Phe Asp Val Leu 685 690 695 GTA TAT GGG AAC GCT GGC AAG πC AAC ATC ATC CCC ACC Aπ ATC AGC 1134 Val Tyr Gly Asn Ala Gly Lys Phe Asn He He Pro Thr He He Ser 700 705 710 TCG GTG GCG GCC πC ACT TCT GTG GGA GTG GGC ACT Gπ CTC TGT GAC 1182 Ser Val Ala Ala Phe Thr Ser Val Gly Val Gly Thr Val Leu Cys Asp 715 720 725 ATC ATC CTG CTC AAT πc CTC AAA GGG GCT GAT CAC TAC AAA GCC AGG 1230 He He Leu Leu Asn Phe Leu Lys Gly Ala Asp His Tyr Lys Ala Arg 730 735 740 AAG Tπ GAG GAG GTG ACT GAG ACA ACA CTG AAG GGT ACT GCG TCA ACC 1278 Lys Phe Glu Glu Val Thr Glu Thr Thr Leu Lys Gly Thr Ala Ser Thr 745 750 755 760 AAC CCA GTG πC GCC AGT GAC CAG GCC ACT GTG GAG AAG CAG TCT ACA 1326 Asn Pro Val Phe Ala Ser Asp Gin Ala Thr Val Glu Lys Gin Ser Thr 765 770 775 GAC TCA GGG GCC TAT TCT Aπ GGT CAC TAGGGCCTCT TCCCAGGGπ 1373 Asp Ser Gly Ala Tyr Ser He Gly His 780 785 CCATGCTCAC CCπAGGCTG CAGAACCTGC AAACAGGCCA CTCTATCTAA GCAGTCAGGG 1433 GTGGGAGGGG GAGAAGAAGG GCTGCTATTT CTGCTGπCA CCCCAAAGAC TAGATCCAGA 1493 TATCTAGGCC CTCACTGπC AACAGATAGG CAATGCπCC CACTAAGACT TGAATCπGC 1553 CTTTACCCCT TGCATGCCTC CCACCTGCπ CCCTGGATCC CAGGACAGCA GCATCCACCC 1613 CTTTCCAAAG GAπGAGAAA ATGGTAGCTA AGGπACACC CATAGGACCT ACCACGTACC 1673 AAGCACπCC ACACATAπA TCCCTnTCA CCCπAAAAT AATCCTATAA GGTAGAAAAA 1733 AAAAAAAAAA AAAAAAAAAA 1753 (2) INFORMATION FOR SEQ ID NO: 9: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 397 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9: Met Asn Cys He Ser Asp Phe Phe Thr Tyr Glu Thr Thr Lys Ser Val 1 5 10 15 Val Val Lys Ser Trp Thr He Gly He He Asn Arg Ala Val Gin Leu 20 25 30 Leu He He Ser Tyr Phe Val Gly Trp Val Phe Leu His Glu Lys Ala 35 40 45 Tyr Gin Val Arg Asp Thr Ala He Glu Ser Ser Val Val Thr Lys Val 50 55 60 Lys Gly Phe Gly Arg Tyr Ala Asn Arg Val Met Asp Val Ser Asp Tyr 65 70 75 80 Val Thr Pro Pro Gin Gly Thr Ser Val Phe Val He He Thr Lys Met 85 90 95 He Val Thr Glu Asn Gin Met Gin Gly Phe Cys Pro Glu Asn Glu Glu 100 105 110 Lys Tyr Arg Cys Val Ser Asp Ser Gin Cys Gly Pro Glu Arg Phe Pro 115 120 125 Gly Gly Gly He Leu Thr Gly Arg Cys Val Asn Tyr Ser Ser Val Leu 130 135 140 Arg Thr Cys Glu He Gin Gly Trp Cys Pro Thr Glu Val Asp Thr Val 145 150 155 160 Glu Met Pro He Met Met Glu Ala Glu Asn Phe Thr He Phe He Lys 165 170 175 Asn Ser He Arg Phe Pro Leu Phe Asn Phe Glu Lys Gly Asn Leu Leu 180 185 190 Pro Asn Leu Thr Asp Lys Asp He Lys Arg Cys Arg Phe His Pro Glu 195 200 205 Lys Ala Pro Phe Cys Pro He Leu Arg Val Gly Asp Val Val Lys Phe 210 215 220 Ala Gly Gin Asp Phe Ala Lys Leu Ala Arg Thr Gly Gly Val Leu Gly 225 230 235 240 He Lys He Gly Trp Val Cys Asp Leu Asp Lys Ala Trp Asp Gin Cys 245 250 255 He Pro Lys Tyr Ser Phe Thr Arg Leu Asp Gly Val Ser Glu Lys Ser 260 265 270 Ser Val Ser Pro Gly Tyr Asn Phe Arg Phe Ala Lys Tyr Tyr Lys Met 275 280 285 Glu Asn Gly Ser Glu Tyr Arg Thr Leu Leu Lys Ala Phe Gly He Arg 290 295 300 Phe Asp Val Leu Val Tyr Gly Asn Ala Gly Lys Phe Asn He He Pro 305 310 315 320 Thr He He Ser Ser Val Ala Ala Phe Thr Ser Val Gly Val Gly Thr 325 330 335 Val Leu Cys Asp He He Leu Leu Asn Phe Leu Lys Gly Ala Asp His 340 345 350 Tyr Lys Ala Arg Lys Phe Glu Glu Val Thr Glu Thr Thr Leu Lys Gly 355 360 365 Thr Ala Ser Thr Asn Pro Val Phe Ala Ser Asp Gin Ala Thr Val Glu 370 375 380 Lys Gin Ser Thr Asp Ser Gly Ala Tyr Ser He Gly His 385 390 395 (2) INFORMATION FOR SEQ ID NO: 10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 2643 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (vi) ORIGINAL SOURCE: (A) ORGANISM: Homo sapiens (vii) IMMEDIATE SOURCE: (B) CLONE: human P2x (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION:174..1370 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 10: GCCTCCAGCT GACCTCTGGC TCCTGTCCTC TGGCTCCACC TGCACCGCCC TGCTCπCCT 60 AAGGGGCCAG GAAGCCCCCA GAAGCTCTAC CATCGACGTG GGTGGTGGCA CCCGGCTCAC 120 CCTGAGAGCA GAGGGCGTGC AGGGGGCTCA GπCTGAGCC CAGCCGGCCC ACC ATG 176 Met GCA CGG CGG πC CAG GAG GAG CTG GCC GCC πC CTC πC GAG TAT GAC 224 Ala Arg Arg Phe Gin Glu Glu Leu Ala Ala Phe Leu Phe Glu Tyr Asp 400 405 410 ACC CCC CGC ATG GTG CTG GTG CGT AAT AAG AAG GTG GGC Gπ ATC πc 272 Thr Pro Arg Met Val Leu Val Arg Asn Lys Lys Val Gly Val He Phe 415 420 425 430 CGA CTG ATC CAG CTG GTG GTC CTG GTC TAC GTC ATC GGG TGG GTG TTT 320 Arg Leu He Gin Leu Val Val Leu Val Tyr Val He Gly Trp Val Phe 435 440 445 CTC TAT GAG AAG GGC TAC CAG ACC TCG AGC GGC CTC ATC AGC AGT GTC 368 Leu Tyr Glu Lys Gly Tyr Gin Thr Ser Ser Gly Leu He Ser Ser Val 450 455 460 TCT GTG AAA CTC AAG GGC CTG GCC GTG ACC CAG CTC CCT GGC CTC GGC 416 Ser Val Lys Leu Lys Gly Leu Ala Val Thr Gin Leu Pro Gly Leu Gly 465 470 475 CCC CAG GTC TGG GAT GTG GCT GAC TAC GTC TTC CCA GCC CAG GGG GAC 464 Pro Gin Val Trp Asp Val Ala Asp Tyr Val Phe Pro Ala Gin Gly Asp 480 485 490 AAC TCC πC GTG GTC ATG ACC AAT πc ATC GTG ACC CCG AAG CAG ACT 512 Asn Ser Phe Val Val Met Thr Asn Phe He Val Thr Pro Lys Gin Thr 495 500 505 510 60 CAA GGC TAC TGC GCA GAG CAC CCA GAA GGG GGC ATA TGC AAG GAA GAC 560 Gin Gly Tyr Cys Ala Glu His Pro Glu Gly Gly He Cys Lys Glu Asp 515 520 525 AGT GGC TGT ACC CCT GGG AAG GCC AAG AGG AAG GCC CAA GGC ATC CGC 608 Ser Gly Cys Thr Pro Gly Lys Ala Lys Arg Lys Ala Gin Gly He Arg 530 535 540 ACG GGC AAG TGT GTG GCC πc AAC GAC ACT GTG AAG ACG TGT GAG ATC 656 Thr Gly Lys Cys Val Ala Phe Asn Asp Thr Val Lys Thr Cys Glu He 545 550 555 TTT GGC TGG TGC CCC GTG GAG GTG GAT GAC GAC ATC CCG CGC CCT GCC 704 Phe Gly Trp Cys Pro Val Glu Val Asp Asp Asp He Pro Arg Pro Ala 560 565 570 Cπ CTC CGA GAG GCC GAG AAC πc ACT Cπ πC ATC AAG AAC AGC ATC 752 Leu Leu Arg Glu Ala Glu Asn Phe Thr Leu Phe He Lys Asn Ser He 575 580 585 590 AGC TTT CCA CGC πC AAG GTC AAC AGG CGC AAC CTG GTG GAG GAG GTG 800 Ser Phe Pro Arg Phe Lys Val Asn Arg Arg Asn Leu Val Glu Glu Val 595 600 605 AAT GCT GCC CAC ATG AAG ACC TGC CTC TTT CAC AAG ACC CTG CAC CCC 848 Asn Ala Ala His Met Lys Thr Cys Leu Phe His Lys Thr Leu His Pro 610 615 620 CTG TGC CCA GTC πC CAG CU GGC TAC GTG GTG CAA GAG TCA GGC CAG 896 Leu Cys Pro Val Phe Gin Leu Gly Tyr Val Val Gin Glu Ser Gly Gin 625 630 635 AAC πC AGC ACC CTG GCT GAG AAG GGT GGA GTG Gπ GGC ATC ACC ATC 944 Asn Phe Ser Thr Leu Ala Glu Lys Gly Gly Val Val Gly He Thr He 640 645 650 GAC TGG CAC TGT GAC CTG GAC TGG CAC GTA CGG CAC TGC AGA CCC ATC 992 Asp Trp His Cys Asp Leu Asp Trp His Val Arg His Cys Arg Pro He 655 660 665 670 TAT GAG πC CAT GGG CTG TAC GAA GAG AAA AAT CTC TCC CCA GGC πC 1040 Tyr Glu Phe His Gly Leu Tyr Glu Glu Lys Asn Leu Ser Pro Gly Phe 675 680 685 AAC πc AGG πr GCC AGG CAC TTT GTG GAG AAC GGG ACC AAC TAC CGT loss Asn Phe Arg Phe Ala Arg His Phe Val Glu Asn Gly Thr Asn Tyr Arg 690 695 700 CAC CTC πC AAG GTG Tπ GGG Aπ CGC πT GAC ATC CTG GTG GAC GGC 1136 His Leu Phe Lys Val Phe Gly He Arg Phe Asp He Leu Val Asp Gly 705 710 715 AAG GCC GGG AAG TTT GAC ATC ATC CCT ACA ATG ACC ACC ATC GGC TCT 1184 Lys Ala Gly Lys Phe Asp He He Pro Thr Met Thr Thr He Gly Ser 720 725 730 GGA Aπ GGC ATC Tπ GGG GTG GCC ACA Gπ CTC TGT GAC CTG CTG CTG 1232 Gly He Gly He Phe Gly Val Ala Thr Val Leu Cys Asp Leu Leu Leu 735 740 745 750 Cπ CAC ATC CTG CCT AAG AGG CAC TAC TAC AAG CAG AAG AAG πc AAA 1280 Leu His He Leu Pro Lys Arg His Tyr Tyr Lys Gin Lys Lys Phe Lys 755 760 765 TAC GCT GAG GAC ATG GGG CCA GGG GCG GCT GAG CGT GAC CTC GCA GCT 1328 Tyr Ala Glu Asp Met Gly Pro Gly Ala Ala Glu Arg Asp Leu Ala Ala 770 775 780 ACC AGC TCC ACC CTG GGC CTG CAG GAG AAC ATG AGG ACA TCC 1370 Thr Ser Ser Thr Leu Gly Leu Gin Glu Asn Met Arg Thr Ser 785 790 795 TGATGCTCGG GCCCCAACTC CTGACTGGGT GCAGCGTGAG GCπCAGCCT GGAGCCCTGG 1430 TGGGTCCCAG CCAGGGCAGA GGGGCCTCCC CAGGAAGTCT CCTACCCTCT CAGCCAGGCA 1490 GAGAGCAGπ TGCCAGAAGC TCAGGGTGCA TAGTAGGAGA GACCTGTGCA AATCTGAGCT 1550 CCGGCTCCGA CCCCACACAC CCTGAGGGAG GCCTACCCTA GCCTCAGCCG CTCCTGGTGG 1610 GGGAATGGCT GGGGGπGGG CAGGACCCTC CCACACACCT GCACCCTAGC πCGTGCTTC 1670 TCTCTCCGGA CTCTCAπAT CCAACCCGCT GCCTCCATTT CTCTAGATCT GTGCTCTCCG 1730 ATGTGGCAGT CAGTAACCAT AGGTGACTAA AπAAACTAA AATAAAATAG AATGAAACAC 1790 AAAAπCAAT TCCTCGGCTG AACTAGCCAC ATTTCAACTG CTCAGTAGAT ACGTGTGGπ 1850 AGTGGCTGCC ATACTGGACA GCTCGGGGCA TTTTCACTGT CAAAGAAAGT TCTAπAGAC 1910 AGCCCTGCπ GAGCCCTGπ TCπCCTGGC πCGGπTCC CTGGGGAACT TATCGACAAT 1970 GCAAGCTCCT GGGCCCACCC CCAGACCTCC TGAACCAAAA GCTCCAGGGC TGGCCGTATG 2030 ATCTGTGTGG ATGGCAAACT CCCCAGGCCA πCTGGGACC TAAGTTTAAG AAGTGCCGTC 2090 CTCGAACTπ CTGACTCTAA GCTCCTGAGC GGGAGTCAGA CπAGCCCTG AGCCTGCACT 2150 TCCTGπCAG GTGCAGACAC TGAACAGGGT CTCAAACACC πCAGCATGT GTGπGTGTG 2210 CTCACGTGCC ACACAGTGTC TCATGCACAC AACCCAGTGT ACACACCACC TACGTGCACA 2270 CAGCATCCπ CCACACTGTG TATGTGAACA GCTTGGGCCC TGCAAACACA ACCATCTACA 2330 CACATCTACA CCCCCAAGCA CACACACATG GTCCGTGCCA TGTCACCTCC ATAGGGAAAG 2390 GCπCTCTCC AAGTGTGCCA GGCCAGGACA GCCCTCCCAG CCATGAATCC πACTCAGCT 2450 ACCTCGGGπ GGGGTGGGAG CCCCAGCCAA ATCCTGGGCT CCCTGCCTGT GGCTCAGCCC 2510 CAGCTCCCAA GGCCTGCCTG GCTCTGTCTG AACAGAAGGT CTGGGGGAAG CGAGGGGTGG 2570 AGTACAATAA AGGGAATGAG GACAAACAAA AAAAAAAAAA AAAAAAAAAA AAAAAAAAAA 2630 AAAAAAAAAA AAA 2643 (2) INFORMATION FOR SEQ ID NO: 11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 399 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: Met Ala Arg Arg Phe Gin Glu Glu Leu Ala Ala Phe Leu Phe Glu Tyr 1 5 10 15 Asp Thr Pro Arg Met Val Leu Val Arg Asn Lys Lys Val Gly Val He 20 25 30 Phe Arg Leu He Gin Leu Val Val Leu Val Tyr Val He Gly Trp Val 35 40 45 Phe Leu Tyr Glu Lys Gly Tyr Gin Thr Ser Ser Gly Leu He Ser Ser 50 55 60 Val Ser Val Lys Leu Lys Gly Leu Ala Val Thr Gin Leu Pro Gly Leu 65 70 75 80 Gly Pro Gin Val Trp Asp Val Ala Asp Tyr Val Phe Pro Ala Gin Gly 85 90 95 Asp Asn Ser Phe Val Val Met Thr Asn Phe He Val Thr Pro Lys Gin 100 105 110 Thr Gin Gly Tyr Cys Ala Glu His Pro Glu Gly Gly He Cys Lys Glu 115 120 125 Asp Ser Gly Cys Thr Pro Gly Lys Ala Lys Arg Lys Ala Gin Gly He 130 135 140 Arg Thr Gly Lys Cys Val Ala Phe Asn Asp Thr Val Lys Thr Cys Glu 145 150 155 160 He Phe Gly Trp Cys Pro Val Glu Val ASD Asp Asp He Pro Arg Pro 165 170 175 Ala Leu Leu Arg Glu Ala Glu Asn Phe Thr Leu Phe He Lys Asn Ser 180 185 190 He Ser Phe Pro Arg Phe Lys Val Asn Arg Arg Asn Leu Val Glu Glu 195 200 205 Val Asn Ala Ala His Met Lys Thr Cys Leu Phe His Lys Thr Leu His 210 215 220 Pro Leu Cys Pro Val Phe Gin Leu Gly Tyr Val Val Gin Glu Ser Gly 225 230 235 240 Gin Asn Phe Ser Thr Leu Ala Glu Lys Gly Gly Val Val Gly He Thr 245 250 255 He Asp Trp His Cys Asp Leu Asp Trp His Val Arg His Cys Arg Pro 260 265 270 He Tyr Glu Phe His Gly Leu Tyr Glu Glu Lys Asn Leu Ser Pro Gly 275 280 285 Phe Asn Phe Arg Phe Ala Arg His Phe Val Glu Asn Gly Thr Asn Tyr 290 295 300 Arg His Leu Phe Lys Val Phe Gly He Arg Phe Asp He Leu Val Asp 305 310 315 320 Gly Lys Ala Gly Lys Phe Asp He He Pro Thr Met Thr Thr He Gly 325 330 335 Ser Gly He Gly He Phe Gly Val Ala Thr Val Leu Cys Asp Leu Leu 340 345 350 Leu Leu His He Leu Pro Lys Arg His Tyr Tyr Lys Gin Lys Lys Phe 355 360 365 Lys Tyr Ala Glu Asp Met Gly Pro Gly Ala Ala Glu Arg Asp Leu Ala 370 375 380 Ala Thr Ser Ser Thr Leu Gly Leu Gin Glu Asn Met Arg Thr Ser 385 390 395

Claims: CLAIMS 1. A recombinant or isolated DNA molecule encoding a P^ receptor, wherein the receptor: (a) has the amino sequence shown in Figure 1 , Figure 2, Figure 3 or Figure 4; or (b) is substantially homologous to the sequence shown in Figure 1 , Figure 2, Figure 3 or Figure 4; or a fragment of such a DNA molecule, which fragment includes at least 15 nucleotides taken from nucleotides 1 to 813 shown in Figure 1, from the full nucleotide sequences shown in Figures 2 and 3, or from nucleotides 1 to 1744 shown in Figure 4. 2. A recombinant or isolated DNA molecule encoding a P^ receptor, wherein the receptor: (a) has the amino sequence shown in Figure 1 or Figure 4; or (b) is substantially homologous to the sequence shown in Figure 1 or Figure 4; or a fragment of such a DNA molecule, which fragment includes at least 15 nucleotides taken from nucleotides 1 to 813 shown in Figure 1 or from nucleotides 1 to 777 shown in Figure 4. 3. A recombinant or isolated DNA molecule encoding a P^ receptor, wherein the receptor: (a) has the amino sequence shown in Figure 1 ; or (b) is substantially homologous to the sequence shown in Figure 1 ; or a fragment of such a DNA molecule, which fragment includes at least 15 nucleotides taken from nucleotides 1 to 813 shown in Figure 1. 4. A DNA molecule as claimed in any of claims 1 to 3, which encodes a human P 2X receptor. 5. A DNA molecule as claimed in any of claims 1 to 4, which is cDNA. 6. A DNA molecule as claimed in any of claims 1 to 5, which is in the form of a vector. 7. A host cell transformed or transfected with a vector as described in claim 6. 8. A host cell as claimed in claim 7 which is a stably transfected mammalian cell which expresses a P 2X receptor. 9. A preparation of P 2X receptor which is free of protein with which it is naturally associated. 10. A preparation of P 2X receptor which is free of P 2Y receptor. 11. P 2X receptor as prepared by recombinant DNA technology. 12. A peptide fragment of P 2X receptor which includes an epitope which is immunologically non-cross reactive with the RP-2 polypeptide disclosed in Owens et al . ( loc. ci t . ) . 13. An antibody which is specific for an epitope of P 2X receptor which is immunologically non-cross reactive with the RP-2 polypeptide disclosed in Owens et al. ( loc . ci t . ) . 14. An antibody as claimed in claim 13, which is a monoclonal antibody. 15. A cell expressing an antibody as claimed in claim 14. 16. The use of a P 2X receptor or a preparation thereof, as claimed in claim 7, 8 or , as a screen for compounds useful in the treatment or prophylaxis of a human or non- human animal disease or condition. 17. The use of a P 2X receptor or a preparation thereof as claimed in claim 9, 10 or 11 as a screen for identifying a P 2X agonist or a P 2X antagonist. 18. A P 2X agonist or a P 2X antagonist identified by a scrren as described in claim 17. 19. A method for obtaining a DNA molecule according to claim 1, wherein the molecule is obtained by chemical synthesis or by using recombinant DNA technology. 20. A method for obtaining a P 2X receptor comprising expressing the P 2X receptor using a host cell according to claim 8 and, optionallly, purifying the P 2X receptor. 21. A DNA molecule, a P 2X receptor, a P 2X agonist or a P 2X antagonist, a method, or a use, substantially as hereinbefore described, with reference to the accompanying examples.

Inventors: BUELL GARY NUTTER, VALERA SOLEDAD, BUELL, GARY, NUTTER, VALERA, SOLEDAD
Applicants: BUELL GARY NUTTER, GLAXO GROUP LTD, VALERA SOLEDAD, BUELL, GARY, NUTTER, GLAXO GROUP LIMITED, VALERA, SOLEDAD
Application year: 1995
Main classification: C12N15
IPC codes: A61K39, C07H21, C07K14, C07K16, C12N5, C12N15, C12P21, C12R1